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Science never solves a 
problem without creating ten more 
(George Bernard Shaw) 
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Kronisk inflammatorisk artrittsykdom og svangerskapsrelaterte aspekter: 
debut av artrittsykdom etter fødsel, svangerskapsutfall og fertilitet. 
Resultater fra en datakobling mellom et norsk pasientregister og Medisinsk 
Fødselsregister 
 
Bakgrunn: 
Tidligere studier har vist at revmatoid artritt (RA) ofte debuterer etter svangerskap, men om 
dette også gjelder andre artrittformer har vært lite studert. Generelt er første svangerskap 
assosiert med økt risiko for ulike typer komplikasjoner (for eksempel preeklampsi, keisersnitt, 
prematuritet, lav fødselsvekt) i forhold til påfølgende svangerskap. Autoimmun sykdom kan 
også påvirke ulike aspekter ved svangerskap som maternale og føtale komplikasjoner. Lite er 
kartlagt omkring fertilitet og potensiell risiko ved svangerskap hos kvinner med så aktiv 
inflammatorisk revmatisk sykdom at de må bruke sykdomsmodifiserende behandling, og det 
er tidligere ikke gjort separate analyser på utfall av første svangerskap og fødsel i denne 
pasientgruppen.  
Det norske pasientregisteret NOR-DMARD (Norwegian Disease Modifying 
Antirheumatic Drug) inkluderer pasienter fra fylte 18 år med RA, psoriasisartritt (PsA), 
ankyloserende spondylitt (AS), uspesifisert artritt (UA) og voksne pasienter med juvenil 
idiopatisk artritt (JIA) som starter med sykdomsmodifiserende behandling. Registeret ga 
mulighet til å studere svangerskapsrelaterte aspekter i en pasientpopulasjon med høy grad av 
inflammatorisk aktiv sykdom. 
    
Mål: 
Artikkel 1:  
Undersøke hvor stor andel av pasientpopulasjonen som hadde debut av artrittsykdom de første 
to år etter tidspunkt for fødsel for kvinner med RA versus andre artrittformer (OCA). 
Undersøke andel av pasienter med debut av artrittsykdom 0-24 måneder versus 25-48 
måneder etter fødsel for kvinner med henholdsvis RA og OCA.  
(OCA = PsA, AS og UA samlet). 
 
Artikkel 2: 
Undersøke svangerskapsutfall for kvinner med inflammatorisk artrittsykdom, alle diagnoser 
samlet, versus referansepopulasjon fra Medisinsk fødselsregister (MFR) ved å studere utfall 
for både mor og barn og undersøke utfall for første og senere svangerskap separat (para 0, 
para 1+), før og etter diagnosetidspunkt. 
 
Artikkel 3: 
Undersøke fertilitetsrater for kvinner med henholdsvis RA, OCA og JIA versus referanser fra 
Det sentrale folkeregister matchet med pasientenes fødselsår. 
Identifisere andel av kvinner uten barn blant pasientene versus referansepopulasjonene. 
Studere intervallet mellom første og andre svangerskap hos pasientgruppene versus 
referansepopulasjonene. 
 
Metode: 
Data fra 631 kvinner i aldersgruppen 18-45 år fra NOR-DMARD registeret ble koblet med 
data fra MFR. Referansepopulasjoner var fødsler registrert i MFR (artikkel 2) og kvinner fra 
Det sentrale folkeregister matchet med pasientenes fødselsår og deretter koblet med data fra 
MFR (Artikkel 3). 
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Resultater: 
Ved sammenligning av debut av RA versus OCA var det ingen statistisk signifikant forskjell i 
andelen av pasienter med debut av artrittsykdom de første to år etter fødsel, verken for debut 
av artritt etter alle svangerskap samlet eller etter første svangerskap. Kvinner med RA hadde 
en statistisk signifikant insidens topp 0-24 måneder etter fødsel sammenlignet med 25-48 
måneder etter fødsel, både for alle svangerskap totalt og etter første fødsel. Kvinner med OCA 
hadde ikke noen signifikant insidens topp, men en trend ble observert etter første fødsel.  
Pasientene hadde en høyere risiko for fødsler med keisersnitt, både totalt og elektivt, 
sammenlignet med referansegruppen. Denne risikoen var uavhengig av paritet. Alle andre 
observerte forskjeller mellom pasienter og referansepopulasjon var relatert til første 
svangerskap. Pasientene hadde en statistisk signifikant høyere risiko for blødning i 
svangerskapet og induserte fødsler. Barn av førstegangsfødende pasienter hadde statistisk 
signifikant høyere risiko for perinatal mortalitet, hadde en lavere gjennomsnittlig fødselsvekt, 
var oftere premature og var oftere små i forhold til gestasjonsalder (SGA). Svangerskapsutfall 
før diagnose var ikke forskjellig fra referansegruppen.  
Alle pasientgrupper (RA, OCA, JIA)hadde statistisk signifikant lavere fertilitetsrater 
enn referansegruppene etter diagnose, men ikke før. Statistisk signifikant flere pasienter enn 
referanser var barnløse. Vi fant statistisk signifikant lengre intervall mellom første og andre 
svangerskap hos pasientene enn hos kontrollene når første svangerskap var før diagnostisert 
artrittsykdom og andre etter. Ingen signifikante forskjeller i intervallene ble observert når 
både første og andre svangerskap var etter diagnose. 
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Biveiledere: Lorentz M. Irgens, Tore K. Kvien, Kjell Åsmund Salvesen   
Finansieringskilde: Samarbeidsorganet mellom Helse Midt-Norge RHF og NTNU 
 
Ovennevnte avhandling er funnet verdig til å forsvares offentlig for graden PhD i klinisk 
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Definitions and abbreviations 
 
Definitions 
 
Birth order one: first delivery in nulliparous women 
 
Caesarean section total: acute, elective and unspecified forms 
 
Chronic inflammatory arthritides: the dominant clinical feature are joint symptoms and signs 
reflecting inflammation 
 
Fertility: the actual production of offspring 
 
First delivery: first delivery in nulliparous women 
 
Induction of labour: use of amniotomy, oxytocin or prostaglandin 
 
Instrumental deliveries: use of vacuum extraction or forceps 
 
Inter pregnancy interval: time period from the date of the first birth to the first day of the last 
menstrual period before the following pregnancy 
 
Low birth weight: < 2500 gram 
 
Nulliparous women: childless women 
 
Other chronic arthritides: psoriatic arthritis, ankylosing spondylitis and unspecified arthritis 
combined 
 
Perinatal mortality: stillbirths after 16 weeks of gestation and early neonatal deaths (< 7 days) 
 
Preterm birth: < 37 weeks of gestation 
 
SGA: small for gestational age defined as birth weight < 10 percentile for the actual 
gestational age 
 
Validity: an index of how well a test or procedure measures what it is intended to measure or 
an objective index by which to describe how valid a test or procedure is 
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Abbreviations and definitions 
 
ACR: American College of Rheumatology 
 
Anti-CCP: anti-cyclic citrullinated peptide 
 
AS: ankylosing spondylitis 
 
CIA: chronic inflammatory arthritides 
 
CNS: central nervous system 
 
COX: cyclooxygenase 
 
CRP: C reactive protein 
 
CS: Caesarean section 
 
DAS28: disease activity score by 28 joint count 
 
DMARD: disease modifying antirheumatic drug 
 
ESR: erythrocyte sedimentation rate 
 
EULAR: European League Against Rheumatism 
 
FDA: The United States Food and Drug Administration 
 
HCQ: hydroxychloroquine 
 
HLA: human leukocyte antigen 
 
IBD: inflammatory bowel disease 
 
IFN: interferon 
 
IL: interleukin 
 
ILAR: International League Association of Rheumatologists 
 
IRF: interleukin regulatory factor  
 
IRR: incidence rate ratio 
 
JIA: juvenile idiopathic arthritis 
 
MBRN: Medical birth registry of Norway 
 
MFR: Medisinsk fødselsregister 
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MHAQ: modified health assessment questionnaire 
 
MHC: major histocompatibility complex 
 
MIF: macrophage inhibiting factor 
 
MTX: methotrexate 
 
NICU: neonatal intensive care unit 
 
NOR-DMARD registry: The Norwegian Disease Modifying Antirheumatic Drug registry 
 
NPR:  The National Population Registry 
 
NSAID: non-steroidal anti-inflammatory drug 
 
OCA: other chronic arthritides 
 
PsA: psoriatic arthritis 
 
RA: rheumatoid arthritis 
 
RF: rheumatoid factor 
 
SF-36: The medical outcomes study 36-item short form 
 
SGA: small for gestational age 
 
SPSS: The Statistical Package for the Social Sciences  
 
SSZ: sulphasalazine 
 
STATA: Statistics / Data Analysis Programme 
 
TGF: transforming growth factor 
 
TNF: tumor necrosis factor 
 
UA: unspecified arthritis 
 
VAS: visual analogue scale 
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Summary 
 
Pregnancy related aspects of chronic inflammatory arthritides: disease 
onset postpartum, pregnancy outcomes and fertility 
Data from a Norwegian patient registry linked to the Medical Birth Registry of Norway 
 
Background 
It has been known for a long time that rheumatoid arthritis is commonly diagnosed post 
partum, but this issue has only been sparsely studied for other arthritides. It is increasingly 
recognized that autoimmunity can affect every aspect of pregnancy such as fertilization, 
maternal complications and adverse fetal outcomes. In general, first pregnancy is associated 
with higher risk of adverse outcomes than subsequent pregnancies, but outcomes of first 
pregnancy have not been examined separately in women diagnosed with chronic 
inflammatory arthritides (CIA) before. Previous studies have examined possibly 
heterogeneous patient populations. The Norwegian Disease Modifying Antirheumatic Drug 
(NOR-DMARD) registry gave access to study pregnancy related aspects in the most diseased 
women, all treated with synthetic and / or biological DMARDs. The registry includes patients 
with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), juvenile 
idiopathic arthritis (JIA) and unspecified arthritis (UA). 
 
Aims:  
-To investigate the proportion of incident cases of RA compared with other chronic arthritides 
(OCA) during the first 24 months after delivery (OCA= PsA, AS and UA combined). 
-To examine a possible peak of incident cases in the time period 0-24 months versus 25-48 
months after delivery within each diagnostic group (RA and OCA). 
-To examine possible different effects of CIA on pregnancy outcomes with separate analyses 
of outcomes in first birth and subsequent births 
-To examine if a possible negative association with pregnancy outcomes was detectable 
before diagnosis of CIA. 
-To compare fertility rates in women with RA, OCA and JIA with birth year matched 
references from the general population. 
-To investigate the proportion of nulliparous women in each diagnostic group versus in birth 
year matched references 
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-To investigate a possible association between mean number of children and age of CIA 
diagnosis 
-To examine inter pregnancy intervals in RA, OCA and JIA women versus birth year matched 
references 
 
Material and methods: 
Patients with inflammatory arthritides have been enrolled into the NOR-DMARD registry 
since 2001.The patients are included when they start treatment with synthetic and / biological 
DMARDs, but many of the patients have been diagnosed several years before the inclusion. 
Diagnosis and time of diagnosis was recorded from NOR-DMARD. Since 1967 medical data 
on all births in Norway have been recorded in the Medical Birth Registry of Norway 
(MBRN).  
Data of 631 female patients aged 18-45 years and included in the NOR-DMARD 
registry in the period 2001-06 were linked with MBRN. Births until October 2007 were 
included in the linkage. In Paper 1 the time interval between the last child delivery before 
diagnosis and time of diagnosis was identified for each patient and used for analyses. In Paper 
2 first births and subsequent births were analyzed separately, before and after diagnosis. In 
Paper 3 we analyzed fertility before and after diagnosis separately. 
In Paper 2 reference deliveries were non-CIA deliveries selected from MBRN. Patient 
deliveries and reference deliveries were frequency sampled according to time periods of 
delivery. In Paper 3 references were selected from The Norwegian Population Registry. Each 
patient was birth year matched with 100 reference women, and data of each reference women 
was linked to the MBRN. Time of diagnosis of each patient was linked to the corresponding 
references to analyze fertility before and after diagnosis.   
 
Results: 
Paper 1 included 183 patients with RA and 110 patients with OCA, all diagnosed after 
delivery. The proportion of incident cases with onset 0-24 months post partum was not 
statistically significantly different between the diagnostic groups, neither in the analysis of all 
pregnancies, nor in the analysis of first pregnancy separately. A statistically significantly peak 
incidence during 0-24 months was seen in the RA group, both when considering all 
pregnancies and only the first pregnancy. A peak trend in onset of disease was observed after 
birth order one deliveries in the OCA group, but the result did not reach statistical 
significance. 
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 Paper 2 included 128 first births (birth order one) and 151 subsequent births after diagnosis 
and corresponding 286 / 262 births before diagnosis. References were non-CIA deliveries 
from MBRN. A statistically significantly higher rate of Caesarean section, both total and 
elective, was related to all patient deliveries. All other excess risks were related to first birth 
in women diagnosed with CIA. The patients had statistically significantly higher risk of 
vaginal bleeding and labour induction than references. First born children of women 
diagnosed with CIA were statistically significantly more often preterm and small for 
gestational age. They also had statistically significantly lower mean birth weight and higher 
perinatal mortality. Pregnancy outcomes before diagnosis did not differ from the reference 
population. 
 
Paper 3 included 631 patients with 849 children registered in MBRN. Of these, 289 children 
(34 %) were born after time of diagnosis versus 44 % in references. A statistically 
significantly higher proportion of CIA women were nulliparous compared with references, 
and relative fertility rates were statistically significantly reduced in all patient groups. The 
mean number of children in patients was associated with age at time of CIA diagnosis. 
A statistically significantly increased inter pregnancy interval was observed in RA and OCA 
women diagnosed between first and second birth compared with references. No differences in 
intervals were observed in any of the diagnostic groups with both first and second birth after 
diagnosis. 
 
Conclusions: 
Our study has shown that not only RA but also other chronic arthritides may have frequent 
onset after delivery. 
All negative diverging pregnancy outcomes in patients versus references were observed in 
relation to first birth after diagnosis of CIA. A higher risk of CS was related to all births in 
women diagnosed with CIA.  
Fertility was reduced after time of diagnosis for all diagnostic groups compared with age 
matched references.  
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Background 
 
Center for Pregnancy and Rheumatic Diseases was established in 1992 and is located at the 
Department of Rheumatology, St Olav’s Hospital (Trondheim University Hospital). The 
Center is an interdisciplinary pregnancy clinic where patients are monitored and treated 
according to the risks of pregnancy related complications calculated from individual disease 
characteristics and previous pregnancy experience. The women are followed during 
pregnancy and after delivery. Before a planned pregnancy counselling by specialists in 
internal medicine and obstetrics is offered when necessary. During pregnancy monitoring of 
placental function and fetal surveillance by specialists in fetal medicine may also be 
necessary. 
About 40 pregnant women with rheumatic diseases are monitored at the Center every 
year. Due to the important matter and sometimes complicated cases, the Center is also 
consulted about women with inflammatory rheumatic diseases planning pregnancies from 
other regions in Norway, which constitutes about 400 individual consultations per year. By 
the introduction of biological disease modifying anti-rheumatic drugs (DMARDs), evidence 
based knowledge about the impact on fertility, pregnancy and delivery has been increasingly 
demanded. 
The background for this thesis is the special challenge I have met in counselling and 
monitoring women with inflammatory rheumatic diseases treated with synthetic and / or 
biological DMARDs and planning pregnancies. The patients regularly ask for our advice, 
which should build upon evidence based knowledge of our patient population. Thus, research 
is another main task for our Center. In a previous thesis, (Reproductive outcome in women 
with rheumatic diseases. Skomsvoll JF, NTNU, 2003) secular trends in pregnancy outcomes 
were studied in women with inflammatory rheumatic diseases during the years 1967-1995. 
Skomsvoll’s studies were population based with data from the Medical Birth Registry of 
Norway. Although our Center previously has investigated different aspects on pregnancy and 
rheumatic diseases, unanswered questions have remained. Given the small number of patients 
with arthritides being pregnant per year, important research questions may not be answered by 
data from a single center. Therefore a multicenter approach was chosen. The Norwegian 
Disease Modifying Antirheumatic Drug (NOR-DMARD) registry gave access to study 
pregnancy related issues in the included women with chronic inflammatory arthritides. In 
contrast to the previous studies, we wanted to focus on the most seriously affected women 
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treated with synthetic or biological DMARDs. We have investigated pregnancy related 
aspects in this particular patient cohort by studying incident arthritis post partum, pregnancy 
outcomes and fertility.  
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1. Introduction  
 
1.1 Diseases 
According to the World Health Organisation, rheumatic diseases have been divided into four 
main categories: inflammatory rheumatic diseases (i.e. arthritides, connective tissue diseases, 
vasculitides), degenerative rheumatic diseases, soft tissue disorders and rheumatic 
manifestations of non-rheumatic diseases. The Norwegian Disease Modifying Antirheumatic 
Drug (NOR-DMARD) registry comprises inflammatory arthritides which have been focused 
in this thesis; i.e. rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis 
(AS), juvenile idiopathic arthritis (JIA) in adult age and unspecified / undifferentiated arthritis 
(UA). 
 
1.1.1 Rheumatoid arthritis (RA) 
RA is a chronic, inflammatory, autoimmune disease characterised by destructive synovitis. 
Symmetric involvement of the small joints of the hands and feet is common. Additionally, RA 
may affect organs like lungs, kidneys, the vascular system, the bone marrow and the eyes (1). 
American College of Rheumatology (ACR) classification criteria for RA diagnosis are shown 
in Table 1. Traditionally, these criteria have been the most commonly used classification 
criteria for RA. However, new classification criteria for RA have recently been published (2). 
The prevalence of RA is estimated to be about 0.5-1.0 % among Caucasians(3;4).  The 
total annual incidence rate is 25-50 / 100000. Women are affected 2-3 times more frequently 
than men (5-7). In the Oslo RA registry the female : male ratio was found to be  
4 : 1 in the premenopausal age (8).  The peak onset of disease is about 60 years of age (6;7).  
The etiology of RA is still unknown, but genetic and environmental factors are of 
importance for disease susceptibility. Among genes independently associated with RA, one 
located on chromosome 7 seems to have different genetic impact depending on gender, with a 
strong and apparently additive effect on disease status in females (9;10).  
Environmental factors may both increase or reduce the risk of developing RA. 
Smoking, in the presence of human leukocyte antigen (HLA)-DR shared epitope, constitutes a 
major environmental risk factor for developing anti-cyclic citrullinated peptide antibody 
(CCP) positive RA (11). Several studies have investigated possible associations between 
reproductive factors and the risk of RA. While studies generally agree that abortions and 
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stillbirths are not related to the risk of RA (12-16), results for other reproductive factors like 
oral contraceptive use, parity, age at first pregnancy and lactation vary considerably (13-26). 
The impaired physical function in RA patients is caused by a combination of 
inflammation and structural damage (27;28). Further, living with such a chronic, painful and 
disabling disease also has impairment of other dimensions of quality of life (7). In one study 
about one third of RA patients of working age were work disabled within one year after 
disease onset (29). In another study women were reported to have three times higher risk of 
work disability than men (30), and women of premenopausal age have been reported to have 
an even fourfold increased risk of work disability compared with men (31).  
The disease is associated with substantial comorbidity and reduced life expectancy 
(32). The excess in deaths is attributable to infection, cardiovascular disease and respiratory 
disease, but also lung cancer and non-Hodgkin’s lymphoma (33). Some studies suggest that 
the course of disease activity and health status in RA has improved during the last decades 
(34;35), which coincides with better treatment strategies. However, still increased mortality in 
RA patients compared with the general population has been reported (36).  
The inflamed synovium in the rheumatoid joint is characterised by synovial lining 
hyperplasia, influx of inflammatory cells via adhesions molecules on activated endothelial 
cells, and neovascularisation on the synovial tissue (37). T cells, B cells, monocytes / 
macrophages and synoviocytes are cells that play important roles in a cascade of cell-to-cell 
interactions and cytokine mediated events. Tumour necrosis factor (TNF), interleukin (IL)-1, 
IL-6 and IL-17 are among the dominant proinflammtory cytokines which promote the 
breakdown of cartilage and bone-loss (37). 
 
 
Table 1 Rheumatoid arthritis 
 
 1987 ACR criteria (38) 
 
1. Morning stiffness for at least 6 weeks 
2. Arthritis for three or more joint areas for at least 6 weeks 
3. Arthritis of hand joints for at least 6 weeks 
4. Symmetric arthritis for at least 6 weeks 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes 
 
RA is diagnosed if 4 of 7 items are present 
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1.1.2 Psoriatic arthritis (PsA) 
 
Psoriatic arthritis has been defined as an inflammatory, usually seronegative, arthritis 
associated with psoriasis (39). PsA is also classified into the group of seronegative 
spondylarthritides, which is a group of rheumatic diseases that share certain genetic and 
clinical features (inflammatory back pain, asymmetrical oligoarthritis, enthesitis, dactylitis 
and uveitis). Epidemiological, radiological and immunogenetic data support the existence of 
PsA as a specific entity (40;41). The exact prevalence of PsA is not known, but estimates vary 
from 0.1 % to 1 % (3;42;43). The female gender is overrepresented in polyarticular disease 
while oligoarticular and spinal disease is more prevalent in men (44-46). PsA may start at all 
ages (42;47). In a Finnish study the mean age at diagnosis was 46.8 years (48), and in a 
Norwegian study the mean age at onset of arthritis was 35 years (43). 
Studies of environmental risk factors of PsA have focused on infection-related triggers 
and hormones. In a case-control study exposure to rubella vaccination substantially increased 
the risk of PsA as well as trauma (49). In a nested case-control study corticosteroid use 
moderately increased the risk of PsA, and pregnancy decreased the risk (50).  
Various susceptibility genes to PsA have been identified. There is evidence that 
caspase recruitment domain 15 (CARD 15) has a role in PsA (9;51). Class I major 
histocompatibility complex (MHC) chain- related gene A (MICA) may confer additional 
susceptibility to PsA (9;52). Functional cytokine gene polymorphisms have also been 
associated with PsA, with tumour necrosis factor-alpha (TNF- ) -308 and TNF- +252 
polymorphism being significantly associated with age at onset of psoriatic skin disease, 
presence of joint erosions in PsA and progression of joint erosions in early PsA (9;53). HLA-
B27 is strongly associated with axial disease, whereas HLA-B38 and HLA-B39 seem to be of 
more importance in peripheral disease (54). 
Moll and Wright classified PsA into five subgroups; 1) Predominant involvement of 
DIP joints, 2) Arthritis mutilans, 3) Symmetrical polyarthritis ( 5joints), 4) Oligoarthritis  
( 4 joints), 5) Predominantly spondylarthritis. Originally, oligoarthritis was believed to be 
the most frequent pattern (39), but recent studies indicate that more patients have polyarthritis 
and that joint pattern may change over time (42;55;56). The classical Moll and Wright criteria 
for diagnosis are shown in Table 2. A new set of criteria, the classification criteria for 
psoriatic arthritis (CASPAR) criteria, has now been developed (57). 
Burden of disease in PsA is comparable with RA and AS (58). Despite higher disease 
activity and more structural damage in RA patients, patients with PsA report similar 
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impairment of physical functioning and psychosocial aspects of quality of life (58-60),  which 
may be due to the additional burden of skin disease. Women diagnosed with PsA in 
premenopausal age have been reported to have a doubled increased risk of being work 
disabled compared with men (61). Radiological damage develop in up to 47 % of PsA 
patients within two years of disease (62). Mortality is increased in PsA patients, and active 
and severe disease are prognostic indicators for death (43;63).  
Immunohistological studies of PsA have revealed that the synovitis in PsA resembles 
spondyloarthritis more than RA (64). Angiogenesis is a prominent feature in both skin and 
joints in PsA. The most common inflammatory cells are T-lymphocytes (65). High levels of 
TNF have been found in both skin lesions and inflamed synovium (66;67). In psoriatic skin 
disease TNF promotes proliferation of the keratinocytes (68). 
 
Table 2 Psoriatic arthritis 
 
 Moll and Wright criteria (39) 
  
1. An inflammatory arthritis (peripheral and / or sacroiliitis or spondylitis) 
2. The presence of psoriasis 
3. The absence of rheumatoid factor 
 
 
1.1.3 Ankylosing spondylitis (AS) 
 
Ankylosing spondylitis is the major subtype among the spondyloarthritides. AS affects 0.1-
1.4 % of Caucasians (3;69;70), but the prevalence varies across ethnic groups and is 
correlated to the prevalence of HLA-B27 in the population (71). The estimated female: male 
ratio is 1: 2-3 (3;69). Disease onset is most frequent in the third decade of life (72), but a 
slightly higher age at onset of AS is reported in females than in males (44). 
Sacroiliitis is a key feature of AS, and the presence of sacroiliitis is required to fulfil 
the 1984 modified New York classification criteria (73) (Table 3). Inflammation in spinal 
joints and ligament structures with subsequent structural damage results in pain and restricted 
spinal mobility (74;75). New classification criteria for spondyloarthritis have recently been 
published (76;77). 
Epidemiological studies have focused on the genetics behind AS and the strong 
linkage of the major histocompatibility complex (MHC) with AS. Especially the relationship 
to HLA-B27 is well known (78). About 90-95 % of AS patients are HLA-B27 positive, as 
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compared to 7-8 % of the general population. The risk of developing AS is about 5 % in 
HLA-B27 positive individuals. However, HLA-B27 accounts for only a third of the total 
genetic effect (79;80). The search for an association between AS and non-MHC genes has 
gained much interest. Two new loci for AS have been identified; ARTS1 and IL-23R and 
another strong non -MHC linkage is located to chromosome 16q (9).  
Few environmental risk factors and triggers have been studied in AS. Two studies 
support the hypothesis that bacterial antigens, especially from the gut flora, play a role in AS 
pathogenesis (81;82).  
AS has impact on functional status, health related quality of life and work disability 
(83;84). Some studies also indicate an increased mortality, especially among men (85;86) 
With longstanding AS, men tend to have more severe radiographic abnormalities than 
women, but women report worse physical functioning than men (83). Women are also 
reported to have more peripheral arthritis than men (44;87).  
The pathology in AS is characterised by bony formation with fusion of joints and 
intervertebral spaces. Inflammation located to enthesial sites causes bone destruction with 
subsequent repair and deposition of chondrogenic matrix that eventually remodel into bone 
(88). In sacroiliac joint biopsies in patients with AS, T cells, macrophages as well as abundant 
TNF messenger RNA have been found (89). TNF has proinflammatory properties, but it is 
also an inhibitor of bone formation. Thus, other pathways and cytokines may be of 
importance in AS structural changes, e.g. wingless (Wnt)-proteins, bone morphogenic 
proteins (BMP) and transforming growth factor beta (TGF)(88).  
 
Table 3 Ankylosing spondylitis 
 
 1984 modified New York criteria (73) 
 
1. Low back pain for at least three months duration improved by exercise and not      
relieved by rest. 
2. Limitation of lumbar spine motion in sagittal and frontal planes 
3. Chest expansion decreased relative to normal values for age and sex 
4. Unilateral sacroiliitis grade 3-4 
5. Bilateral sacroiliitis grade 2-4 
 
Definite AS if criterion number 4 or 5 and any clinical criterion (1-3) 
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1.1.4 Juvenile idiopathic arthritis (JIA) 
 
Juvenile idiopathic arthritis is the most frequent chronic inflammatory rheumatic disease 
during childhood. The criteria for diagnosis and classification have changed over the years 
(90). In 1972 the American College of Rheumatology (ACR) established criteria for juvenile 
rheumatoid arthritis (JRA), and the criteria was revised in 1977. In Europe the term juvenile 
chronic arthritis (JCA) was used. The European League Against Rheumatism (EULAR) 
established criteria for JCA in 1977. In 1997 the International League of Associations of 
Rheumatologists (ILAR) introduced the term juvenile idiopathic arthritis (JIA) which 
included seven different subgroups of the disease (91). Sets of classification criteria for JRA, 
JCA and JIA are shown in Table 4 (90). The main three groups are polyarticular, 
pauciarticular and systemic disease. In this thesis the term JIA is used. 
Twin studies indicate a genetic component of JIA. In monozygotic twins both siblings 
were affected in 44 % compared to 4 % in dizygotic twins (92). HLA-DR 8 was associated 
with disease development in most of the JIA subgroups (enthesitis related arthritis, oligo- and 
polyarthritis) (93-95).  HLA-B27 was associated to juvenile entesitis related arthritis (94;96). 
An association between JIA and genes coding for proinflammatory cytokines and cytokine 
receptors (IRF-1, TNF-, IL-1Ra, IL-6, MIF) has been demonstrated (97).  
Among the environmental risk factors studied, infection remains the most favoured of 
candidates. However, quite few studies have appeared. 
The incidence of juvenile arthritis varies around the world. In Scandinavia an annual 
incidence of 11-23 / 100000 / year has been reported (98-101). The prevalence rates have 
varied from 86 in western Sweden to 148 / 100000 in northern Norway (98;100). About 17-20 
% of children with incident arthritis have JIA (99;101), and about 60 % of the children who 
develop JIA are girls (99;101). A peak incidence is reported between 1 and 3 years of age and 
another peak between 10 and 13 years (101;102). 
As many as 50 % of all JIA patients may still have active disease in grown-up life. In 
children with oligoarticular disease, about 50 % of patients will progress into polyarticular 
disease (5 or more affected joints) as adults (103;104). Children with polyarticular disease, 
regardless if they have rheumatoid factor or not, have the highest risk of a remaining active 
disease the rest of their lives. Many of these patients will need synthetic and / or biologic 
DMARD treatment in adult life. In children with systemic onset JIA 37 % may develop 
chronic destructive polyarthritis in adult life (105;106).  
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One study of JIA demonstrated a mortality of 2 % within 15 years of disease onset 
compared with less than 1 % in the general population (107;108).  JIA related heart disease 
and amyloidosis were the most frequent causes of death, followed by infections and 
intoxications (109). Data from a national registry in Scotland have reported an increased life 
time mortality risk of 5 in women and 3 in men with JIA compared to the general population 
(110). The ratio between observed and expected mortality was higher for JIA than RA 
patients (110).  
 
 
 
Table 4 Classification criteria for arthritis in childhood (90) 
 
Criteria ACR EULAR ILAR 
Terminology Juvenile rheumatoid 
arthritis (JRA) 
Juvenile chronic 
arthritis (JCA) 
Juvenile idiopathic 
arthritis (JIA) 
Age at disease onset <16 years <16 years <16 years 
Duration of 
arthritis 
6 weeks 3 months 6 weeks 
Included subgroups Systemic 
Polyarticular 
 
Pauciarticular 
Systemic 
Polyarticular 
 
Pauciarticular 
 
 
 
Psoriatic arthritis 
Juvenile AS 
 
Arthritis associated 
with IBD 
Systemic 
Polyarticular RF- 
Polyarticular RF+ 
Oligoarticular, 
persistent 
Oligoarticular, 
extended 
Psoriatic arthritis 
Enthesitis related 
arthritis 
Unspecified arthritis 
 
Excluded 
subgroups 
Juvenile AS 
Juvenile psoriatic 
arthritis 
Arthritis associated 
with IBD 
  
ACR = American College of Rheumatology, EULAR = European League Against 
Rheumatism, ILAR = International League Association of Rheumatologists, IBD = 
inflammatory bowel disease, RF =  rheumatoid factor, AS = ankylosing spondylitis 
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1.1.5 Unspecified arthritis (UA) 
 
Patients without a well-defined inflammatory arthropathy are labelled to have unspecified / 
undifferentiated arthritis. Some patients develop features to permit a later classification, 
whereas others remain undifferentiated, but with persistent joint inflammation, functional 
disability and development of radiographic joint damage. UA is common, with an estimated 
prevalence between 30 and 50 % of patients with arthritis presenting to rheumatologist (111-
117). The patients fail to fulfil criteria for specific disorders such as PsA, RA or parvovirus 
B19 infections, and the diagnosis is usually one of exclusion. In patients with unspecified 
polyarthritis 13-60 % have a self-limited inflammatory joint disorder (112;116), however, 
unspecified polyarthritis is not always a benign disorder. In a Dutch study of undifferentiated 
arthritis, 60 % had a self -limited disease, 16 % developed a persistent, seronegative, non-
erosive polyarthritis and 24 % an erosive, largely seropositive polyarthritis (118). In this study 
predictors for treatment with DMARD or the development of joint damage were presence of 
persistent synovitis at 3 months of disease, rheumatoid factor positivity, anti-CCP positivity, 
elevated erythrocyte sedimentation rate or C-reactive protein level 10 mg/l, female sex and 
the presence of early radiographic erosions.   
Another study has compared MR imaging of the knees in patients with unspecified 
oligoarthritis, established RA or spondyloarthropathy. Patients with RA showed more 
destructive changes in terms of synovial thickening, bone marrow edema, cartilaginous and 
bone erosions compared with UA and spondylarthropathy (119). 
 
 
1.2 Medications 
 
1.2.1 Drug treatment of chronic inflammatory arthritides 
 
The majority of patients included in this thesis had used or were using non steroidal anti-
inflammatory drugs (NSAIDs) (including cyclooxygenase 2 inhibitors) and corticosteroids in 
addition to the use of synthetic and / or biological disease modifying anti rheumatic drugs 
(DMARDs).  
NSAIDs inhibit prostaglandin synthesis by blocking cyclooxygenase enzymes. 
Prostaglandins are important mediators of pain and inflammation. Thus, the analgesic and 
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anti-inflammatory properties of NSAIDs make their use frequent in patients with all types of 
inflammatory arthritides. In AS therapy with NSAID is the first drug of choice (120).  
Corticosteroids are potent anti-inflammatory medications and widely used in RA, JIA 
and UA, but more seldom in PsA and AS.  
 
Synthetic disease modifying anti-rheumatic drugs (DMARDs) 
In inflammatory active RA, PsA, JIA and UA treatment with synthetic DMARDs are 
commonly used and include methotrexate (MTX), sulphasalazine (SSZ), leflunomide, 
hydroxychloroquine (HCQ) and gold compounds. Gold compounds have been used for 
treatment of RA during several decades, but less common during the last decade because of 
new treatment options. The DMARDs azathioprine, D-penicillamine and cyclosporine are 
over the recent years infrequently used in the treatment of inflammatory arthritides and are 
not considered in this thesis.  
Methotrexate (MTX) is a dihydrofolate reductase inhibitor that inhibits folic acid 
metabolism and purine synthesis (121).  MTX is prescribed extensively in treatment of RA, 
both as monotherapy and in combination with other synthetic or biological DMARDs. MTX 
is also used in the treatment of PsA, JIA and UA. Oral MTX has a half life of 3 to 10 hours, 
but can persist in the liver for several months (122).  
Sulphasalazine (SSZ) is a folic acid antagonist and is mainly used to treat patients with 
RA and inflammatory bowel disease (IBD). Its half-life is between 5 and 10 hours.  
Leflunomide is an inhibitor of dihydroorotate dehydrogenase and thus inhibits 
pyrimidine synthesis (123). The medication is mainly used for treatment of RA, but also of 
PsA. Leflunomide has a half-life of 14 days, but its active metabolite undergoes extensive 
enterohepatic circulation and may persist in the body for up to 2 years (124).  
Hydroxychloroquine (HCQ) is an antimalarial agent used to treat patients with lupus/ 
connective tissue disease or mild to moderate RA. Although its exact mechanism of action is 
unknown, it is thought to interfere with the presentation and processing of antigens (121). Its 
half-life is appro.ximately 8 weeks, and with this slow elimination the medication may persist 
in the body for months after discontinuing therapy. 
 
Biological DMARDs   
During the last decade treatments targeting specific cytokines or molecules involved in the 
inflammatory disease process have become available for use in clinical practice (125). Three 
anti- tumour necrosis factor-alpha inhibitors; infliximab, etanercept and adalimumab have 
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been commercially available during the time of inclusion of patients for the studies in this 
thesis. Infliximab is a chimeric anti-TNF- monoclonal antibody (IgG1), etanercept is a TNF-
 receptor p75 IgG1 construct, and adalimumab is a TNF receptor-IgG fusion protein (126). 
Infliximab, etanercept and adalimumab bind directly to TNF- preventing activation of its 
receptor on targeting cells (127). Anti-TNF therapy is indicated for active inflammatory 
disease in RA, PsA and JIA when not responding on traditional DMARD therapy, and in AS 
if treatment with NSAIDs is without response (128). Recently, two new TNF--inhibitors 
have also been commercially available, certolizumab and golimumab. Certolizumab is a 
pegylated, humanized anti-TNF Fab fragment, and golimumab is a fully human monoclonal 
antibody (129). 
Anakinra is a recombinant IL-1 receptor antagonist approved for treatment of 
moderate to severe RA.  Its use in RA has been limited, given the poor efficacy of Anakinra 
on RA and availability of superior medications.  
Other treatment options have also been commercially available in the treatment of RA 
during the last years. Rituximab is a chimeric murine / human monoclonal antibody directed 
against CD-20 antigen expressed on the surface of B-lymphocytes and induces lysis of 
CD20+ B lymphocytes. Tocilizumab is a humanized monoclonal antibody against interleukin 
6 receptor, and abatacept is a human cytotoxic T-lymfocyte-associated antigen 4-IgG1 fusion 
protein, blocking T-cells by binding to costimulatory proteins present on antigen-presenting 
cells. 
 
 
1.2.2 Drug treatment of chronic inflammatory arthritides (CIA) in pregnancy 
 
To avoid destruction of joints, involvement of internal organs, severe disability and even 
increased mortality, disease control with medication is essential in patients with CIA. 
In women with CIA who plan to become pregnant, a therapeutic regimen is required that 
quickly induces remission or maintains improvements. In addition, the regimen should be 
compatible with pregnancy. These requirements exclude several highly efficient 
immunosuppressive and biologic drugs and reduce the possibilities of combination therapies. 
However, in RA the disease course itself may improve during pregnancy. Retrospective and 
small prospective studies have reported improvement of disease activity in as many as 70-90 
% of pregnant patients with RA (130). On the other side two large prospective studies have 
used validated measurements of disease activity and found improvements during pregnancy in 
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only 63 % and 48 % of the patients, respectively (131;132), and even less than 20 % of the 
patients reported complete remission (131). Consequently, some form of drug treatment will 
be necessary for 40-50 % of pregnant RA patients (130).  
Generally, women with CIA are advised to plan their pregnancies in periods where the 
disease activity is low. Managements strategies and recommendations for prescribing 
antirheumatic drugs during pregnancy may differ by region depending on guidelines 
published by national specialist associations (130).  
The United States Food and Drug Administration (FDA) safety category classification 
of pharmacotherapies for use during pregnancy have published recommendations and 
warnings about use of medications before conception and during pregnancy (Table 5). 
Although the FDA category classification is almost exclusively based on animal reproductive 
data, physicians and patients use it as an important resource. However, the FDA classification 
is limited in its ability to precisely predict the human risk (133). 
 
 
 
 
Table 5 The United States (US) Food and Drug Administration safety category 
classification of pharmacotherapy for use during pregnancy (134) 
 
Category Description 
A Adequate and well-controlled studies in pregnant women fail to demonstrate a 
risk to the fetus in the first trimester and no evidence of a risk later in pregnancy  
B Animal studies fail to demonstrate a risk to the fetus and no adequate and well-
controlled human data available 
C Animal studies have revealed no evidence of harm to fetus, however, there are 
no adequate and well-controlled studies in pregnant women  
Or 
Animal studies have shown an adverse effect, but adequate and well-controlled 
studies in pregnant women have failed to demonstrate a risk to the fetus 
D Animal studies have shown an adverse effect, and there are no adequate and 
well-controlled studies in pregnant women 
or 
No animal studies have been conducted, and there are no adequate and well-
controlled studies in pregnant women 
X Animal or human studies demonstrate fetal abnormalities, and there is evidence 
of human fetal risk based on investigational / marketing experience in humans / 
risks clearly outweigh any potential benefit 
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1.2.2.1 NSAIDs 
 
Effects on fertility 
Prostaglandins are involved in ovulation and implantation. Several case reports and small 
series have described transient infertility following treatment with indomethacin, diclofenac, 
piroxicam and naproxen (135-137). Studies in animals and humans have shown that NSAIDs 
can inhibit rupture of the luteinized follicle and thereby cause infertility (136). Still, we lack 
epidemiological data about chronic users of NSAIDs are at increased risk of infertility.  
Cyclooxygenase (COX) 2 is expressed in preovulatory follicles and inducing the maturation 
of the ovum. In rats and mice inhibition of both COX 1 and COX 2 interfere with fertilisation, 
implantation and decidualisation (136;138).  
 
Early and mid-pregnancy  
NSAIDs cross the placenta and enter the fetal circulation (139). A few studies have found 
possible fetal lesions like oral cleft, cardiac and gastric defects related to NSAID use in early 
pregnancy (140;141), whereas others could not confirm these findings (142;143). Two 
population-based cohort studies have shown an association between use of NSAID early in 
pregnancy and miscarriages, but causal association was not established (142;143). Traditional 
NSAIDs are considered category B medications (Table 5). Thus, it is advisable to use 
NSAIDs with short half-life and at the lowest effective dosage in early and mid-pregnancy. 
 
Late pregnancy 
The use of NSAID in late pregnancy and a premature closure of ductus arteriosus is a well 
documented association (144). Renal dysgenesis and oligohydramnion have also been 
reported (145). Thus, NSAIDs are contraindicated beyond 32 weeks of gestation. 
 
COX-2 inhibitors 
There are not adequate safety data in human pregnancy concerning the use of COX-2 
selective inhibitors, and they are classified as category C medications (Table 5). It is advisable 
to avoid these medications during pregnancy. 
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1.2.2.2 Corticosteroids 
 
Maternal considerations 
Corticosteroids such as hydrocortisone, cortisone and prednisone cross the placenta, but are 
rendered biologically inactive by placental enzymes. Thus, they can be used to treat maternal 
disease during pregnancy. Use of corticosteroids during pregnancy is associated with an 
increased risk of pregnancy-induced hypertension, preeclampsia and gestational diabetes 
(146;147). In addition, corticosteroid side effects in pregnant women include other well-
known side effects like osteopenia, osteonecrosis and susceptibility to infections. Pregnancy 
specific complications like premature rupture of the membranes are also reported more 
frequently in patients using corticosteroids (148). 
Corticosteroids are classified as category B medications (Table 5), and they can be 
used throughout pregnancy, either on a daily dosing or in a tapering schedule to manage 
flares. To avoid pregnancy complications, the cumulative amount should be minimized to the 
smallest dose required to control the symptoms. 
 
Fetal considerations    
One meta-analysis has reported increased risk of oral cleft defects with first-trimester 
exposure to corticosteroids like hydrocortisone and prednisone (149), however, two other 
large studies did not demonstrate increased risk of birth defects with use of these medications 
(150;151). A Dutch study in women with RA showed lower birth weight in infants of mothers 
using prednisone in pregnancy (152). Fetal adrenal suppression is rare (153). 
Fluorinated corticosteroids (dexamethasone and betamethasone) cross the placenta and 
are used to prevent conditions such as respiratory distress syndrome and cerebral 
haemorrhage in the preterm newborn given as a single antenatal dose (154). However, animal 
studies suggest that repeated antenatal steroid doses can interfere with the growth and 
development of the immature brain (155;156). Human studies have also indicated that 
repeated antenatal steroid doses may have a negative effect on the neuropsychological 
development of the child (157-159). Possible negative effects seem linked more to 
dexamethasone than betamethasone, and it has been suggested that betamethasone should be 
preferred when available (154;160;161). 
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1.2.2.3 Synthetic DMARDs 
 
Methotrexate (MTX) 
MTX crosses the placenta. Experience with MTX in human pregnancy has been derived 
mainly from patients treated for cancer with multiagent therapy and MTX used in high doses 
(154). High-dose MTX exposure during pregnancy is associated with a specific pattern of 
cranial, central nervous system and limb defects referred to as the aminopterin / methotrexate 
syndrome (162). A fetal exposition of methotrexate therefore may lead to malformations of 
the skull, facial dysmorphism, CNS anomalies with lower intelligence and defects of the 
extremities as well as intrauterine growth restriction (163). The most vulnerable time for 
embryotoxicity has been suggested to be between 5 and 8 weeks of gestation (164). However, 
fetal malformations have also been observed before five weeks and after 11 weeks of 
gestation (165).  
There are inadequate data to determine the outcomes of pregnancy exposed to low-
dose MTX (5-20 mg weekly) as used in RA, JIA, PsA and UA. The malformation rate in the 
rheumatic diseases is difficult to calculate because only small retrospective case series on RA 
are reported, and they lack detailed information. However, a high rate of spontaneous abortion 
has been reported (166). MTX is labelled as a category X drug (Table 5). To avoid fetal 
exposition the use of MTX should be discontinued at least 3 months before conception. 
 
Leflunomide 
Leflunomide is reported to be embryo toxic in animal studies (167) and one case of blindness 
has been reported in a preterm born baby (168). Because of the long persistence of the active 
metabolite of leflunomide, the drug has to be discontinued and eliminated using 
cholestyramine before pregnancy. After cholestyramine chelating therapy, women should wait 
at least 3 menstrual cycles before attempting pregnancy. So far there is lack of data on the 
safety of leflunomide in human pregnancy, and it is labelled as a category X drug (Table 5). 
 
Hydroxychloroquine (HCQ)  
HCQ crosses the placenta. Concerns regarding its fetal toxicity were based on reports of 
retinal and ototoxicity in humans exposed to chloroquine, a related antimalarial agent 
(169;170). Although available data do not suggest increased fetal risk with exposure (171-
173), HCQ is classified as a category C drug (Table 5), but it may be used in pregnancy when 
indicated. 
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 Sulphasalazine (SSZ) 
Both SSZ and its metabolite sulphapyridine cross the placenta, and equal concentrations of 
the drugs are found in the maternal serum and cord serum (174). No reports of teratogenicity 
exists for women with inflammatory bowel disease using SSZ (175;176). Two case-control 
studies have shown a possible increased risk of oral cleft, neural tube and cardiovascular 
defects in pregnancies exposed to different folic acid antagonists including SSZ (177;178), 
but another study could not confirm these findings (179). Thus, available data indicate that the 
potential risk of teratogenicity is low, and SSZ is classified as a category B drug (Table 5). 
SSZ may be used during pregnancy with folate supplementation. 
 
Gold compounds 
Gold compounds cross the placenta (180;181) and have been found in fetal liver and kidneys. 
There are few reports of pregnancy outcomes in women taking gold compounds, and no 
evidence of an increase in neonatal malformations in the small number of pregnancies 
reported (182). Gold sodium thiomalate is classified as a category C drug (Table 5). 
 
1.2.2.4 Biological DMARDs 
 
There are no available human data on the use of anakinra during pregnancy, but animal 
studies have not found any fetal malformations. Anakinra is classified as a category B 
medication (Table 5). 
 In animal studies using analogous anti-TNF antibody, no evidence of teratogenicity 
has been observed (183). However, experience with TNF- inhibitors is still limited. Most 
concerns have been about the use of TNF- inhibitors during first trimester of pregnancy.  
The MHC class I-related Fc receptor mediates the transmission of IgG1 across the placenta 
(184). Thus, all anti-TNF agents containing the Fc receptor will pass the placenta.  Significant 
trans placental passage of the monoclonal antibodies infliximab and adalimumab takes place 
from the second trimester of pregnancy onwards, and their levels increase in cord blood to 
reach levels similar to or higher than maternal levels at term(130;185;186). Long-term effects 
of intrauterine exposure to TNF- inhibitors have not been studied (187). The anti-TNF 
agents adalimumab, etanercept and infliximab, are classified as category B drugs by the FDA 
(Table 5) and continuation of anti-TNF treatment in pregnancy is an issue under debate. The 
current expert opinion is to avoid the drugs after a positive pregnancy test. In women with 
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very active inflammatory disease in pregnancy, the current expert opinion is that anti-TNF 
treatment may be continued until gestational week 30. Use of anti-TNF in pregnancy should 
always be in agreement with the pregnant women and depend on the severity of disease and 
judgement of risks versus benefits.  
 Certolizumab is the only of the present available anti-TNF agents without Fc receptor, 
and there is no active transport over the placenta. So far there has been only a few casuistic 
reports from human pregnancies and without any adverse effects. Due to limited experience, 
certolizumab is recommended to stop 5 months before planned pregnancy. No human 
pregnancy reports exist for the new anti-TNF agent golimumab, and so far discontinuation is 
recommended 6 months before conception. 
Studies in pregnant animals have shown that abatacept crosses the placenta. No human 
pregnancy reports exist neither for abatacept nor tocilizumab, and discontinuation is 
recommended 3 months before conception for both agents.   
Only a few casuistic reports exist on rituximab treatment in pregnancy. All of these 
pregnancies were in women treated with rituximab for malignant or haematological diseases. 
Lymphopenia was noted in one of two neonates after first-trimester exposure to rituximab 
(130;188;189). In three of six cases treated with rituximab during second and third trimester, 
serum levels of rituximab were similar in the mothers and their newborns, and the infants had 
greatly reduced or undetectable numbers of B cells (130;190-192). Rituximab is classified as 
a category C drug by the FDA (Table 5), and discontinuation 12 months before pregnancy is 
recommended.   
 
 
2 Why pregnancy may influence chronic inflammatory arthritides (CIA) 
and vice versa 
 
2.1 Immunology in relation to pregnancy in women with chronic inflammatory 
arthritides 
   
Pregnancy induces physiological changes in the maternal immune system in order to protect 
the fetus from immunological attack by the mother. Research over the past decade has 
indicated that no general immunosuppression takes place in the maternal system. Rather, there 
is a shift from prevailing Th1 response to a type Th2 response (193;194). CD4+ T cells can be 
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divided into two subsets: one is the T helper 1 type characterized by production of interferon  
(IFN ), interleukin (IL)-12, tumour necrosis factor-  (TNF- ) and IL-2 and involved in cell 
mediated immunity. The other T cell subset consists of Th2 committed cells, which mainly 
produce IL-4, IL-10 and IL-13, thereby enhancing humoral immunity. The immunological 
changes taking place during and after pregnancy may modulate disease symptoms according 
to the underlying pathophysiology of the disease in question. 
 IFN is a major contributor to a Th1 immune response, up regulating Th1 cell 
differentiation and inhibiting Th2 cell development. IL-1 and TNF- are proinflammatory 
cytokines that contribute to synovitis and joint destruction in both RA and AS (195-197). The 
immune modulating activities of cytokines are also regulated by soluble cytokine receptors 
like TNF- receptor (TNFR) which can buffer the biological effects of TNF- (198). Another 
natural inhibitory mechanism involves the blocking of receptor binding by cytokine receptor 
antagonists like IL-1Ra (199).  
RA is regarded as a T-cell mediated and Th1 response-driven disease (200). The 
frequently reported ameliorating effect of pregnancy on RA (201-203), is possibly caused by 
the increased immune tolerance and shift from Th1 towards Th2 differentiations of T cells 
with increased secretion of the anti-inflammatory cytokines IL-4 and IL-10. IL-10 down- 
regulates production of proinflammatory cytokines by Th1 cells and macrophages. In 
pregnancy IL-10 counteracts pregnancy related disorders, such as fetal growth restriction, 
fetal death and preeclampsia (194-197;204;205). The increase in the anti-inflammatory 
cytokines is driven by high concentrations of circulating hormones, such as cortisol, oestrogen 
and progesterone as well as endogenous corticosteroids (203;206). RA disease development is 
mitigated by oestrogen, and pregnancy typically suppresses disease activity (207). In contrast, 
there is often a flare in the disease during the postpartum period, which is associated with a 
sudden fall in hormones after delivery, and a high concentration of prolactin during 
breastfeeding (208). 
Amelioration of RA during pregnancy has also been associated with a disparity in 
HLA class II antigens between mother and fetus (202). These findings suggest that the 
maternal immune response to paternal HLA antigens may have a role in the pregnancy-
induced remission of RA. 
Recently, the role of galactosylation of IgG during pregnancy has been discussed as 
disease remitting factor in pregnant patients with RA, but so far the question remains whether 
the observed increase in galactosylation is an epiphenomenon or a true remission-inducing 
factor (209;210).  
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In difference to RA, AS often remains active and is mitigated only in late pregnancy 
(44;211), and an aggravation of disease symptoms is commonly seen within the first six 
months after delivery. In AS a Th0 or Th2 type immune response is predominant (205).  
A recent study has demonstrated that pregnancy influenced the expansion and cytokine 
secretion of T-regulator (Treg) cells in both patients with AS and controls without AS. 
However, in contrast to observations in the controls, the Treg cells of pregnant patients with 
AS failed to support an anti-inflammatory cytokine milieu and thereby possibly contributing 
to the persistent disease activity of AS during pregnancy (212). 
In PsA, JIA and UA no explicit studies on immunological changes during pregnancy 
exist. 
 
 
2.2 The effect of pregnancy on inflammatory arthritides 
 
Most studies have focused on RA and the frequently reported ameliorating effect of 
pregnancy (201;213-217). However, one study has demonstrated a widespread variability in 
the effect of pregnancy on the disease activity (131), and another found that remission during 
pregnancy was not as frequent as previously reported (132). Improvement of disease activity 
during pregnancy may not be associated with changes in levels of autoantibodies during 
pregnancy, but seems to occur more frequently in the absence of anti-CCP and RF (218). Post 
partum a disease flare is reported in 90 % of the women within 6 months (207;219). 
Studies of pregnant women with AS have demonstrated unchanged or even worse 
disease activity during pregnancy. Remission has been confined to patients with 
accompanying diseases like psoriatic skin disease, inflammatory bowel disease and small 
joint arthritis (211;216;217;220). A flare during the first 3 months post partum was reported  
in about 90 % of the pregnancies (217).  
In PsA one study has reported improvement or even remission in 80 % of the 
pregnancies and a postpartum flare within 3 months in 70 % (217). In the same study 
quiescent JIA was not reactivated by pregnancy, and active disease at conception ameliorated 
in about 60 % (217). A post partum flare was reported in about 50 % of the women with JIA 
(217). In a Polish study 52 % of patients with early onset pauciarticular juvenile chronic 
arthritis had a post partum flare after delivery (221). The flares were most frequent in women 
who had active disease before pregnancy, and in those who had experienced a flare after a 
previous pregnancy and / or were breast feeding. 
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2.3 Incident arthritis post partum 
 
Onset of RA is found to be rare during pregnancy but more frequent after delivery, with a 
peak incidence during the first twelve months post partum (214;222;223). It is difficult to 
predict incidence rates of arthritides after delivery, but a prospective Japanese study found 
that the incidence of RA was 0.08 % during the first year after delivery (214). A British report 
from 1950 concluded that RA occurred in 19 % within 1 year after pregnancy, and in 29 % 
during the first two years among all patients with RA under the age of 45 (224). Oka found 
that 12.6 % of patients with RA had disease onset within 1 year after delivery (214).  
Breast feeding has been reported both to increase the risk of RA onset (17), and to 
reduce the risk of RA onset post partum. (18;23;225). Particularly the risk was reduced if the 
breast feeding was long- term (18;23). Further, some studies have reported that oral 
contraceptive use may protect against the development of RA (17;25;26), but other studies 
have been unable to confirm this  effect (17;22).  
Whether this pattern of incident arthritis post partum occurs also in other types of 
chronic arthritides, including PsA, AS and UA, has only been sparsely studied. A few 
published results indicate increased onset of PsA (226) and AS (227) post partum.  
 
 
 
2.4 The effect of inflammatory arthritides on pregnancy, delivery and the infant 
 
Autoimmunity can affect every aspect of pregnancy including fertilisation, maternal 
complications and adverse fetal outcomes (228). Also, effects of subclinical disease processes 
on pregnancy outcomes can not be excluded since a status of preclinical RA may exist (229-
231).  
The impact of CIA on pregnancy and delivery have been addressed in several studies 
(152;232-241). In earlier studies published in 1969 (242) and in 1983 (243) unfavourable 
effects on the fetus were not observed, however, this contrasts results of later studies. 
 The rate of miscarriage / spontaneous abortion in women with RA differ between the 
studies. Higher (244), lower (16) or similar rates (235-237) compared with controls have been 
reported. Increased rates of caesarean section (CS) have been reported in patients with CIA 
 39
and in specific diagnostic groups as RA, AS and JIA (227;232-235;238;245).  Additionally, 
preeclampsia seems to occur frequently in RA and in CIA (234;238;240;241). 
Increased proportions of preterm delivery (235;238;239), small for gestational age (SGA) 
infants and low birth weight (<2500 g) (232;234;238;239) as well as lower mean birth weight 
(152;232) have been reported in CIA pregnancies compared with references. A Dutch study 
has reported that both a high disease activity and use of low doses of prednisone during 
pregnancy may influence birth weight negatively (152).  
Very few studies have reported on birth defects, perinatal and neonatal deaths 
(237;239;246). One study concluded with a slightly increased rate of birth defects and a 
significantly higher rate of post perinatal mortality, but not perinatal mortality in infants of 
mothers with CIA (239). 
Only a few studies have addressed pregnancy outcome in women before the diagnosis 
of CIA and without any adverse reports compared with controls (236;246), except for a report 
of increased  perinatal deaths among infants of women who subsequently developed RA after 
delivery (237). 
 
First births 
Generally, pregnancy and delivery complications are more frequent in first pregnancy (247-
249). The risk of CS in nulliparous women with spontaneous start of labour, cephalic fetus 
and no previous scar has been reported to be 2.5 times higher than for comparable parous 
women (250). The causes for this increased risk are not fully understood, although it has been 
known for more than 40 years (251;252). Separate analyses of outcomes of first delivery and 
subsequent deliveries in women with CIA have not been previously published. 
 
 
 2.5 Fertility in women with chronic inflammatory arthritides 
 
CIA may influence the production of offspring (fertility), and different mechanisms may be 
involved: physical, psychological, hormonal or immunological as well as medical treatments 
(136). Significantly lower mean number of births, shorter time span in reproduction, longer 
inter pregnancy interval and reduced subsequent pregnancy rate have been reported in women 
with inflammatory arthritides compared with references in a Norwegian population based 
study (253). 
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 Fertility has particularly been studied in RA. Some studies indicate reduced sexual 
desire and lower frequencies of intercourse in women with RA (254-256). In structured 
interviews with about 400 married women with RA, nearly one out of five answered that the 
arthritic disease influenced childbearing decisions, and especially in those diagnosed at young 
age (257). The overall percentage of women having children was not different from the 
general population, but women with RA were more likely to opt for a single child (257). 
 Data obtained in cross sectional surveys have suggested low ability to conceive a child 
and longer time to achieve pregnancy in women with RA both before and after disease onset 
(258;259). However, a case-control study did not find any differences in number of children 
between cases and age matched controls (260). 
 Normal fertility has been reported in women with AS (220;227;261), however, a 
longer time to achieve pregnancy (136;261) have been reported in women with AS. 
 Long term physical and psychosocial impairment found in adult patients diagnosed 
with JIA may explain the longer time to achieve pregnancy (245;262). Fertility do, however, 
not seem to be impaired (262). In PsA and UA no explicit reports on fertility exist. 
 
 
 
3. Materials and Methods 
 
3.1 Data sources 
 
3.1.1 The Norwegian Disease Modifying Antirheumatic Drug (NOR-DMARD) registry 
(263) 
 
The NOR-DMARD registry was established in December 2000. From the beginning, three 
Norwegian rheumatology departments (Diakonhjemmet Hospital in Oslo, Lillehammer 
Hospital for Rheumatic Diseases and University Hospital of Northern Norway in Tromsø) 
recruited patients. In 2002 the registry was expanded with two additional rheumatology 
departments (St Olav’s Hospital in Trondheim and Buskerud Central Hospital in Drammen). 
The five NOR-DMARD centers cover about 1.4 million inhabitants. Adult patients (18 
years) with inflammatory arthropathies are consecutively included in the registry when they 
start with a new DMARD treatment and are followed longitudinally. Each DMARD regimen 
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represents one case, and a patient will be included as a new case if there is a change in 
prescription of a DMARD regimen. By August 2006, 5811 cases were registered in about 
3700 different patients. The completeness of the registry is about 85 % and has been quite 
stable over the years. The remaining cases have either been missed for inclusion, excluded 
due to language barriers, refused enrolment or been enrolled in ongoing randomised clinical 
trials. The registry has received an annual grant from the Norwegian Directorate of Health and 
Social Affairs. Otherwise the conduct of the registry has been financed through unrestricted 
research grants from different pharmaceutical companies (Abbott, Amgen, Aventis, MSD, 
Schering Plough / Centocor, Wyeth, BMS, Roche and UCB). The sponsors have no influence 
on data collection, analyses, manuscript preparation or publications. 
 
3.1.2 The Medical Birth Registry of Norway (MBRN) (264;265) 
 
The registry was established on the basis of compulsory notification introduced in Norway in 
1967 and is since 2002 organised under the Norwegian Institute of Public Health. 
Surveillance and detection of secular changes in perinatal health as well as epidemiological 
research are the main objectives of the MBRN.  
For each birth a notification form is sent within the ninth day post partum. A revised 
and more detailed notification form has been used since December 1, 1998 (Appendix). From 
1967 to 1998 the registry collected data on all deliveries in Norway after 16 weeks of 
gestation. Since December 1, 1998, all deliveries after 12 weeks of gestation have been 
registered.  
Complete ascertainment of the births is ensured through a record linkage with the 
National Population Registry. The birth attendant completes the standardized form with 
demographic data on the child, the father and the mother, data on maternal health during 
pregnancy, complications and procedures during delivery and the condition of the child at 
birth. The national identification number enables linkage of births into sibships. 
 
3.1.3 The National Population Registry 
 
The National Population Registry (Det Sentrale Folkeregisteret) was established in 1964 and 
includes data about everyone residing in Norway. Data about citizens living in Norway are 
gathered for tax, electoral and population analyses by local tax offices. The registry is run by 
the Directorate of Taxes (Skattedirektoratet). Data from the National Population Registry, i.e. 
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names, addresses, citizenship, identification numbers, position of employment and civil status 
of people, are only accessible to authorised public sector offices. However, members of the 
public may apply for data from the National Population Registry for legal purposes including 
research. 
 
3.2 Classification of diagnoses in the NOR-DMARD registry 
 
Patients in the NOR-DMARD registry are diagnosed by a treating rheumatologist and 
classified according to the WHO international classification of diseases (ICD-10). For further 
analyses patients are classified as follows: 
 
1.  RA (M05.0, M05.1, M05.2, M05.8, M05.9, M06.0, M06.8, M06.9) 
2.  PsA (L40.5, M07.0, M07.1, M07.2, M07.3) 
3.  AS (M45) 
4.  JIA (M08.0, M08.1, M08.2, M08.3, M08.4, M08.8, M08.9) 
5. Unspecified arthritis (M13.0, M13.9, M13.1, M02.9, M79.0)  
 
3.3 Data collection / logistics 
 
All patients give written informed consent before enrolment in the NOR-DMARD. The data 
are collected at baseline and at follow-up visits after 3, 6 and 12 months, and yearly thereafter. 
Each center has a research nurse working on the project. The standard operating procedures 
are as follows: At each visit the patients are seen both by the research nurse and the treating 
physician. The patients fill in the self-assessment forms. The nurses collect data on 
demographics, previous treatment, education and life style and the utilisation of health care 
resources. They also register ESR and CRP, do joint counts and measure blood pressure. The 
physicians register all data related to medical history including time of diagnosis, disease 
manifestations, treatment adjustments and adverse events. The research nurses check the 
completeness of the registrations. 
 All the CRFs are handled and computerised centrally by Smerud Medical Research 
AS, who also request additional information when data are missing. Data files are returned to 
Diakonhjemmet hospital for quality check before analyses. 
 
 43
3.4 Assessments in NOR-DMARD  
 
The following assessments are included in NOR-DMARD: 
 
 Age and gender 
 Diagnosis 
 Patient history including educational level, working status, date of diagnosis of 
the inflammatory rheumatic disease, age at diagnosis and smoking habits 
 32 swollen and 32 tender joint counts (28 joint counts plus forefeet and ankles) 
and calculation of DAS-28 
 Rheumatoid factor present or absent 
 Anti-CCP present or absent (registered since 2006) 
 Erosions present or absent 
 ESR and CRP 
  
 Investigator’s global assessment of health status on a 100 mm visual analogue 
scale (VAS) 
 Patient’s assessment of pain, fatigue and global health status on 100 mm VAS 
 MHAQ 
 SF-36 
 Comorbidities 
 Utilisation of health care 
 Previous treatment: DMARD / biologics, corticosteroids, NSAIDs / COXIBs 
 Current medication, including start of DMARD and / or biologics 
 
Adverse events and patient priorities for treatment are recorded at follow-up. Treatment 
terminations and reasons for stopping treatment are also registered.  
 
From 2006 the Bath Ankylosis Spondylitis Activity Index (BASDAI), the Bath Ankylosing 
Spondylitis Functional index (BASFI) and a utility measure, EQ-5D, were added to the case 
report form.  
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The disease activity score-28 (DAS-28) is computed based on 28 tender- and swollen joint 
counts, patient’s global assessment on a 100 mm VAS and the erythrocyte sedimentation rate 
(ESR). The formula is shown in the Appendix. 
 
The MHAQ (0-4) is a modified version of HAQ and comprises one question within each of 
eight categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip and 
usual activities (266). The score ranges from 0 (good functioning) to 4 (poor functioning). 
The questionnaire has been translated to Norwegian. 
 
The Medical Outcome Study 36-item Short Form (SF-36) is a commonly used generic health 
status measure. It originated in the USA (267;268), and has been translated and validated for 
use in Norway (269;270). It contains 36 questions measuring health across eight different 
dimensions: physical functioning, role limitations due to physical health problems, bodily 
pain, vitality, social functioning, role limitation due to emotional problems, mental health and 
general health. A score is computed within each dimension with a value from 0 (worse 
possible health state) to 100 (best possible health state). 
 
3.5 Assessments from the NORD-DMARD registry used in this thesis 
  
Gender 
Age at inclusion 
 Diagnosis 
 Date of diagnosis 
 Age at diagnosis 
 Date of inclusion in NOR-DMARD 
28 joint counts and DAS-28 
Rheumatoid factor present or absent 
Erosions present or absent.  
 
 
3.6 Study population: Data linkage of NOR-DMARD and MBRN 
Data of female patients aged 18 – 45 years at the time of inclusion in the NOR-DMARD 
registry in the period 2001-2006 were included in this thesis. Eligible women received written 
information about the planned linkage of NOR-DMARD data and MBRN. Fourteen women 
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opted out, and data of 631 women from the NOR-DMARD registry were linked with the 
MBRN. The linkage included deliveries until October 2007. Indirectly, the linkage identified 
the proportion of women without children. 
 
 
3.7 Reference population from the Medical Birth Registry of Norway (MBRN) 
The reference deliveries were frequency sampled from non-CIA deliveries in MBRN. The 
proportion of deliveries was equal for each decade among CIA patients and references. This 
procedure created two reference groups comprising 800000 reference deliveries after 
diagnosis and 1000000 before (Paper 2). 
  
3.8 Reference population from the Norwegian Population Registry 
Each woman included in the NOR-DMARD study was birth-year- matched with 100 
randomly selected women from the Norwegian Population Registry (n= 63100 references). 
Each of the references was linked to the MBRN (Paper 3).  
 
4 Statistics 
 
The Statistical Package for the Social Sciences for Windows software, versions 15.0, 16.0 and 
17.0, (SPSS, Chicago, IL, USA) and Statistics / Data Analysis (STATA), version 10.1 and 
11.0 (StataCorp, Lakeway Drive College Station, Texas, USA) were used for statistical 
analyses.  
All hypothesis testing was conducted assuming a 0.05 significance level ( = 0.05) and a two-
sided alternative hypothesis. 
 
4.1 Group comparisons 
Group differences were explored using Pearson Chi-Square tests for categorical variables and 
Mann-Whitney U-test for continuous variables. In the tables, values are displayed as 
percentages for categorical variables and mean (standard deviation (SD)) for continuous 
variables. 
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4.2 Survival analysis 
Kaplan Meier plots were used to visualise the proportion of patients without disease during 
the first 5 years after delivery. The curves start at time of delivery, and time to event is time to 
diagnosis in years (Paper 1). 
 
4.3 Regression analyses 
 
4.3.1 Multiple linear regression analysis 
Analyses of birth weights and head circumferences were analysed in multiple linear 
regression analyses with covariates for gestational age, gender, maternal age and parity when 
relevant (Paper 2). 
 
4.3.2 Logistic regression analysis 
Associations between chronic inflammatory arthritides and adverse pregnancy outcomes 
(Paper 2) were assessed in logistic regression analyses with adjustments for maternal age. In 
addition, analyses on birth weight <2500 g and transfer to neonatal intensive care unit (NICU) 
were adjusted for gestational age. 
 
4.3.3 Cox regression analysis 
The proportions of incident cases of RA and OCA with diagnosis 0-24 months after delivery, 
were estimated by Cox multiple regression analyses with adjustments for potential 
confounding variables as maternal age at delivery and birth order (Paper 1). 
               Comparisons of inter pregnancy intervals between the first and second birth in 
patients and references were estimated  by Cox multiple regression analyses with adjustment 
for maternal age at first delivery (Paper 3).   
 
4.3.4 Poisson regression analysis 
Poisson regression analysis with adjustment for population at risk was applied to estimate 
incidence rate ratio (IRR) of disease 0-24 versus 24-48 months post partum (Paper 1). 
              Poisson regression analysis was used to estimate relative fertility rates in women 
with RA, OCA and JIA before and after diagnosis versus references. Adjustment was done for 
parity at time of diagnosis when relevant (Paper 3). 
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4.3.5 Locally weighted Scatterplot Smoothing (Lowess Fit) 
The regression analysis with Lowess Fit was used to calculate and visualise mean number of 
children by age of diagnosis (Paper 3). 
 
 
5 Legal and ethical aspects 
 
The NOR-DMARD study was conducted according to the ethical principles of the 
Declaration of Helsinki. All patients had signed a written informed consent form before 
enrolment in the NOR-DMARD registry. 
Permission to use data from MBRN was given by the Publication Board of the 
MBRN. The eligible women for the data linkage received written information about the 
planned linkage of NOR-DMARD data with the MBRN, and they were given the opportunity 
to withdraw from the study. The Norwegian Data Inspectorate, the Regional Ethics 
Committee of Central Norway and the Norwegian Directorate of Health approved the study. 
Permission to use data from the Norwegian Population Registry was given by  
the Norwegian Tax Authorities and the Regional Ethics Committee of Central Norway. 
 
 
6 General aim and specific research questions 
 
6.1 General aim 
 
The general aim of this thesis was to examine pregnancy related aspects of chronic 
inflammatory arthritides in women treated with synthetic and /or biological DMARDs. 
 
6.1.1 Specific aims 
 
Paper 1: 
Incident cases post partum  
-To investigate the proportion of incident cases of RA compared with other chronic 
inflammatory arthritides (OCA) during the first 24 months after delivery. 
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-To examine a possible peak of incident cases in the time period 0-24 months versus 25-48 
months after delivery within each diagnostic group (RA and OCA).  
 
Paper 2:  
The impact of CIA on pregnancy outcomes in women treated with synthetic or 
biological DMARDs (Reference deliveries from the Medical Birth Registry) 
-To examine possible different effects of CIA on pregnancy outcomes with separate analyses 
of outcomes in first birth and subsequent births in women treated with disease modifying 
antirheumatic drugs. 
-To examine if a possible negative association with pregnancy outcomes was detectable 
before diagnosis of CIA. 
 
Specific aims: 
-to estimate proportion of assisted reproduction 
-to estimate risk of pregnancy complications: vaginal bleeding, preeclampsia 
-to estimate risk of delivery complications: induction of labour, caesarean section, 
excessive vaginal bleeding >500 ml during delivery 
-to estimate the risk of adverse perinatal outcomes: preterm birth, SGA, mean birth 
weight and head circumference in relation to gestational age, major birth defects, 
transfer to neonatal intensive care unit (NICU) and perinatal mortality 
 
 
Paper 3: 
Fertility (Reference population from the Norwegian Population Registry) 
To compare fertility rates in women with RA, other chronic arthritides (OCA) and JIA with 
birth year matched references from the general population. 
To investigate the proportion of nulliparous women in each diagnostic group versus in birth 
year matched references 
To investigate a possible association between mean number of children and age of CIA 
diagnosis 
To examine inter pregnancy intervals in RA, OCA and JIA women versus birth year matched 
references 
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7 Summaries of results 
 
7.1 Paper 1 
Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a 
patient register linked to a medical birth registry 
 
In all, 69 (37.7 %) of 183 patients with RA and 31 (28.2 %) of 110 patients with OCA 
developed arthritis within 2 years post partum versus 27 (14.8 %) and 20 (18.2 %), 
respectively, during the next two years. The relative risk (RR) (95 % CI) of incident RA 
versus OCA diagnosed 0-24 months post partum was 1.41 (0.92, 2.16) (p=0.10), unadjusted. 
Adjusted for maternal age at delivery and birth order RR (95 % CI) was 1.38 (0.89, 2.12)  
(p=0.14). 
         When we examined incident arthritis after first pregnancy separately, 30 (41.1 %) of 73 
patients with RA and 14 (31.8 %) of 44 patients with OCA developed arthritis within 2 years 
post partum versus 9 (12.3 %) and 5 (11.3 %) during the next two years. Unadjusted, RR (95 
% CI) of incident RA versus OCA diagnosed 0-24 months post partum after first delivery was 
1.37 (0.73, 2.60) (p=0.32). Adjusted for maternal age at delivery RR (95 % CI) was 1.01 
(0.52, 1.93) (p=0.97).  
         When considering all pregnancies, the Incidence Rate Ratio (IRR) (95% CI) for 
diagnosis 0-24 months versus 25-48 months was 1.73 (1.11, 2.70) (p=0.01) for RA and 1.05 
(0.59, 1.84) (p=0.86) for OCA. The IRR was 2.23 (1.06, 4.70) (p=0.03) and 1.87 (0.67, 5.21) 
(p=0.22), respectively when only considering diagnosis after the first pregnancy. 
          The proportions of incident cases with onset 0-24 months after delivery did not reach 
statistically significantly difference in the comparison between RA and OCA. A statistically 
significantly peak incidence during 0-24 months was seen in the RA group, both when 
considering all pregnancies and only the first pregnancy. In the OCA group we did not 
observe a statistically significantly increased peak incidence, but a trend was observed after 
birth order one. 
 
 
 50
7.2 Paper 2 
Pregnancy and delivery in women with chronic inflammatory arthritides with a specific 
focus on first birth  
 
We analysed 128 first births and 151 subsequent births after diagnosis and corresponding  
286 / 262 births before diagnosis and compared the results with the reference population.   
Assisted reproduction was more frequent in patients with first birth compared with 
references, but did not reach statistically significance after adjustment for maternal age at 
delivery (OR 1.77 (0.69, 4.53) (p=0.23). Vaginal bleeding in pregnancy was more frequently 
observed in patients with first birth, adjusted OR 2.01 (1.00, 4.13) (p=0.05).  
Caesarean section (CS) was observed more frequently in all patient deliveries 
compared to references. Adjusted OR for CS total in first birth was 1.51 (1.00, 2.29) (p=0.05) 
and in subsequent births 1.79 (1.19, 2.68) (0.004), and for elective CS 2.60 (1.43, 4.75) (p= 
0.002) and 2.18 (1.33, 3.58) (p=0.002), respectively. A higher rate of labour induction was 
observed in women with first birth, adjusted OR 1.61 (1.08, 2.41) (p=0.02).  
 First born infants of women diagnosed with CIA were more often preterm (OR 1.85 
(1.09, 3.13) (p=0.02) and small for gestational age (OR 1.60 (1.00, 2.56) (p=0.05), and they 
had higher perinatal mortality (OR 3.34 (1.06, 10.51) (p=0.04) compared with references. 
First born infants of women diagnosed with CIA also had lower mean birth weight and 
smaller head circumference than the references (p=0.01 and 0.05, respectively) when adjusted 
for gestational age, gender and maternal age at delivery.     
No excess risks in pregnancies prior to CIA diagnosis were observed for any birth 
order compared with references, except for an increased risk of preeclampsia after adjustment 
for maternal age in women with subsequent births. 
             
 
7.3 Paper 3 
Fertility in women with chronic inflammatory arthritides 
 
Among 631 patients 849 children were registered in MBRN. Of these, 289 children (34.0 %) 
were born after time of diagnosis versus 44.3 % in references. In the diagnostic groups 147 
children were registered in the RA group, 89 in the OCA group and 53 in the JIA group after 
diagnosis. 
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Altogether 206 of 631 (32.6 %) patients were childless versus 26.4 % in references 
(p<0.001). Among RA patients 28.4 % (96 of 338) were nulliparous versus 24.5 % in 
references (p=0.09), 30.7 % (67 of 218) in OCA patients versus 24.5 % in references (p=0.03) 
and 57.3 % (43 of 75) in JIA patients versus 40.9 % in references (p=0.004). 
Mean number of children was associated with age at diagnosis of CIA. Adjusted 
relative fertility rates in RA, OCA and JIA after diagnosis were 0.88, 0.84 and 0.84, 
respectively compared with references (p<0.001 for all diagnostic groups). Relative fertility 
rates in patients before diagnosis were not reduced. 
We observed significantly increased inter pregnancy intervals in RA and OCA women 
diagnosed between first and second birth compared with references (p=0.003 and p=0.002, 
respectively). No differences in the inter pregnancy intervals were observed in any of the 
diagnostic groups compared with references when both first and second birth were after 
diagnosis. 
 
 
 
8 General discussion 
 
8.1 Study design 
 
8.1.1 Linkage of data between the NOR-DMARD registry and MBRN 
 
The five NOR-DMARD centers cover about 25% of the Norwegian population. Originally, 
the NOR-DMARD registry was designed to study effectiveness of medical treatment 
regimens. However, registries like NOR-DMARD may also be used for other purposes, i.e. 
the linkage of data to other types of registries. Data linkages between two or more registries 
obviously give access to more information than one single registry, but limitations have to be 
considered. In general, registry data are predefined in registries like NOR-DMARD and 
MBRN, and does not give researchers influence on data collection. 
The strengths of the NOR-DMARD registry are the comprehensiveness of the data 
collection; all main diagnoses of inflammatory arthritides in adult patients are included as 
well as nearly all DMARD prescriptions. Only few patients in need of DMARDs were not 
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included in the NORD-DMARD registry, mostly because they refused or were considered not 
eligible.  
            A special strength of the data linkage was possibility to access information about 
perinatal mortality, which very few previous studies of pregnancy outcomes in CIA have had 
access to. Another advantage was that the data linkage indirectly revealed the proportion of 
nulliparous CIA women by lack of match in the MBRN. 
The NOR-DMARD registry is not powered to detect rare adverse events. Thus, the 
linkage of NOR-DMARD and MBRN did not have power to evaluate specific birth defects or 
birth defects in relation to use of medication, and we could not examine pregnancy outcomes 
for each diagnostic group. 
A crucial variable from the NOR-DMARD registry for this thesis was the information 
about time of diagnosis of CIA, which is not registered in the MBRN. This variable was used 
in all of the three publications in the thesis.  
A limitation of the thesis was that NOR-DMARD lacks information about medication 
used during pregnancy. Most female patients planning pregnancies stop DMARDs 
incompatible with pregnancy several months before they attain pregnancy. In the NOR-
DMARD registry patients were withdrawn when they stopped a DMARD regimen and 
reincluded when they started a new DMARD regimen, which means that registrations of 
disease activity scores were not available during pregnancy since most of the women stop 
DMARD medication. Another limitation was lack of variables which could have provided 
useful information in this work, i.e. information about marital /cohabitate status in paper 3. 
In general, the use of linked data is restricted by governmental rules. Especially, 
information about rare outcomes must be carefully managed to avoid publishing potential 
identifiable data of the patient. 
 
    
8.1.2 Patients 
 
For the studies in this thesis we selected patients from the NOR-DMARD registry in the age 
group 18-45 years; the fertile period. Initiation of DMARD regimen was the main entry 
criterion for the NOR-DMARD registry, and all patients in the studies comprising this thesis 
had inflammatory disease treated with DMARD medication (synthetic or biologic).  The 
parous status of the women was unknown until the data linkage between NOR-DMARD and 
MBRN was performed.  
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8.1.3 Reference populations 
 
In Paper 2 the reference deliveries were population based, frequency sampled from non-CIA 
deliveries in MBRN. The proportion of deliveries was equal for each decade among CIA 
patients and references. By using this method we did not have to adjust for time periods of 
delivery in the logistic regression analyses. 
 In Paper 3 references were selected from the Norwegian Population Registry (NPR). 
Each patient (women) was birth year matched with 100 randomly selected women from NPR, 
and data from the NPR women were linked with data from MBRN. Date of diagnosis for each 
patient was linked to the corresponding references. By this method fertility rates before and 
after time of CIA diagnosis could be calculated in patients and references.   
 
 
8.2 Methodological considerations 
 
In Paper 1, the longitudinal case-case design made it possible to study the proportion of cases 
developing RA or OCA during a certain time period after delivery. It was possible to calculate 
incidence rate ratios, i.e. the relationship between incidence rates. 
In Paper 2, we studied outcomes of pregnancies from a registry based patient cohort 
(NOR-DMARD) compared with reference pregnancies from a population registry based 
cohort (MBRN). Single births were the unit of analysis, and a cross sectional design was used. 
All variables pertaining to a birth were recorded during the same pregnancy.  
In Paper 3, the study design was a cohort study, and for each patient 100 birth year 
matched references were randomly selected from the Norwegian Population Registry. We 
identified the number of children at a certain time point (October 2007), but with a 
longitudinal cohort design with sibships, meaning all pregnancies or births to a women (birth 
order 1, 2).  
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8.2.1 Role of chance 
 
In order to quantify the degree of variability accounting for the observed results, we 
performed a test of statistical significance (p-value); p0.05, meaning that there was no more 
than a 5 % probability of observing a result as extreme as that observed due to chance. 
However, a p-value is a composite measure that reflects both the magnitude of the difference 
between the groups and the sample size. Consequently, even a small difference may be 
statistically significant if the sample size is sufficiently large. Confidence interval (CI) may 
also be used, which has been done in all three papers in this thesis: the analyses of incidence 
ratios (Paper 1), the logistic regression analyses of pregnancy outcomes (Paper 2) and the 
analyses of relative fertility rates (Paper 3). The CI provides the range where the true 
magnitude of effects is. The effect of the sample size can be ascertained from the width of the 
confidence interval itself. The narrower the confidence interval, the less variability is present 
in the estimate of effect, reflecting a larger sample size. The wider the confidence interval, the 
greater the variability in the estimate of effect, and the smaller the sample size (271). 
 
8.2.2 Validity and reliability 
 
Validity is divided into internal validity (the degree to which the results of an observation are 
representative for the particular group of people being studied) and external validity (the 
degree to which the results of a study apply to people not in it; generalisability).  
 
8.2.2.1 Internal validity 
 
Internal validity may be reduced by bias and confounding. Bias is the possibility that some 
aspects of the design of a study have introduced an error into the results (i.e. selection bias). 
Confounding can occur when mixing of effects between exposure, the disease and a third 
factor that is associated with the exposure and independently affects the risk of developing 
disease (271). Thus, a confounder must be associated to both the exposure and the disease. 
Confounding can lead to either the observation of apparent differences between study groups 
when they do not truly exist or, conversely, the observation of no difference when they do 
exist. A potential confounder will be an actual confounder if adjustment for the variable 
results in a change in the estimate of the association between the exposure and the disease.  
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In this thesis data were collected from two sources, the NOR-DMARD registry and the 
MBRN. The disease scores (SJC, DAS28), information about RF positivity, erosive disease 
and time of diagnosis were performed, obtained and filled in by trained study nurses or 
doctors. Midwives fill in reports for all deliveries in Norway and send them to MBRN. 
Overall, the internal validity of the data from NOR-DMARD and MBRN is considered as 
good. 
 
8.2.2.2 External validity 
 
The patients of interest were all treated with synthetic and/or biological DMARDs. Thus, the 
results and conclusions from Article 2 and 3 can not be extrapolated to a general population of 
CIA women, from the mildest to the most diseased women, in which only a proportion of the 
patients are using DMARDs. 
 
  
8.2.3 Random errors 
 
Random errors lead to loss of precision. Precision can be improved by increasing the sample 
size. Small samples in some of the subgroups may represent a problem in a few analyses, i.e. 
the analyses of inter pregnancy intervals in Paper 3, the estimate of IRR in the OCA group in 
Paper 1 and for some estimates of Odds Ratio of adverse pregnancy outcomes in Paper 2.  
However, in most analyses the sample sizes were of adequate size.   
 
8.2.4 Selection bias 
 
Selection bias may occur if an exposed individual with adverse outcome is more likely to be 
included and vice versa. However, a strength of the NOR-DMARD registry is the selective 
inclusion restricted to only DMARD prescriptions, i.e. conventional DMARDs as well as 
biologics. 
 Usually, DMARDs are more widely used in patients with RA than in other chronic 
arthritides. This possible bias may have contributed to fewer incident cases in the OCA group 
(Paper 1). 
 Eligible women received written information about the planned linkage of NOR-
DMARD and MBRN data. Fourteen women opted out, and we do not know about these 
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women were childless or had experienced any serious pregnancy outcomes. Over all, these 
women constituted a small proportion (2 %) of all eligible women.    
 
8.2.5 Recall bias 
 
Some mothers may underreport their rheumatic disease. If a possible association between 
adverse pregnancy outcome and rheumatic disease is well known, underreporting would most 
likely apply to women without an adverse pregnancy outcome. This may cause inflated 
relative risk estimates. However, the data on maternal disease were registered independently 
of births and could not cause recall bias. 
 
8.2.6 Confounders 
 
A confounding variable is associated with exposure and not an intermediate link in causation 
(271). We have adjusted for possible confounders such as maternal age at delivery and 
gestational age. 
 Maternal age at delivery was a confounding factor for assisted reproduction (Paper 2). 
Gestational age and maternal age at delivery were confounding factors in the analyses of birth 
weight < 2500 gram in first born children of mothers diagnosed with CIA (Paper 2).  
Due to lack of data on socioeconomic status and educational level in the reference 
groups (Paper 2 and Paper 3), we were unable to adjust for these variables in the logistic 
regression analyses. Norway is a socioeconomically quite homogenous nation compared with 
many other countries. All pregnant women in Norway are offered pregnancy care free of 
charge and with a participation rate close to 100 %. However, previous studies have shown 
that socioeconomic status influences the outcome of musculoskeletal disease, including RA, 
in Norway (272). Furthermore, it has been shown that fertility rates of unemployed women 
are lower than those of employed women in Norway (273).   
 It is known that lifestyle factors including smoking, are associated with infertility 
(274). Even in Norway smoking is associated with lower socioeconomic status (275). 
Smoking habits were not adjusted for due to incomplete data among patients and references 
(Paper 2) or lack of data among references (Paper 3). Smoking habits have been voluntary 
registered in MBRN since the new form from Dec 1 1998, but most of the examined 
pregnancies before diagnosis of CIA were from before 1998. The frequency of smoking 
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during pregnancy has been reduced substantially from 30 % in 1980ies to 10-15 % in 2000-05 
(276-280).  
 
 
8.2.7 Misclassification and ascertainment of diagnoses 
 
The patients included in clinical trials should be true representatives of the population of 
interest. Thus, classification criteria in clinical trials, as opposed to diagnostic criteria, are 
characterised by high specificity. Some commonly used classification criteria are the 1987 
ACR criteria for RA (38), the 1984 modified New York criteria for AS (73) and the Moll and 
Wright criteria for PsA (39). For PsA, the CASPAR criteria (57) have been developed to 
increase the specificity, and new diagnostic criteria for both RA and AS have been published 
(2;76;77). The purpose of the new classification criteria is to include and classify patients in 
an early phase of the disease.  
 The NOR-DMARD registry was originally designed with the main focus on patients 
with RA, and the date of fulfilling the ACR criteria was recorded. Specific information on 
fulfilment of the classification criteria for AS, PsA, JIA and UA were not recorded in the 
NOR-DMARD registry. However, all patients were classified according to the ICD-10 
system, i.e. based on the diagnoses given by rheumatologists. Although the modified New 
York criteria and the Moll and Wright criteria were not formally used, all patients were 
diagnosed by experienced rheumatologists, and the diagnoses are usually based on these 
criteria.  
 Adult patients with JIA were classified as JRA or JCA according to the changing 
terms (Table 4). 
 The group of patients with UA was classified according to the ICD-10 system. All had 
active inflammatory arthritis and were starting synthetic and/or biological DMARDs, but 
some of these patients may have had arthritis secondarily to additional diseases; i.e. 
inflammatory bowel disease. We used the initial diagnosis at time of inclusion in the NOR-
DMARD registry, but some of the patients may have developed characteristics for other 
disease groups later in life. In about 20 % of patients with PsA the rheumatological 
manifestation precede the onset of cutaneous lesions (281). The new classification criteria for 
PsA (CASPAR) include PsA without manifest psoriatic skin disease (PsA sine psoriasis), but 
patients may previously have been misclassified as UA. It is also known that a proportion of 
patients with UA will develop RA (282).  
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 9 Interpretation and comparison with other studies 
 
9.1 Post partum onset of rheumatoid arthritis and other chronic arthritides: results 
from a patient register linked to a medical birth registry (Paper 1) 
  
It has been known for a long time that RA is commonly diagnosed post partum, but this issue 
has not been extensively studied for other arthritides (PsA, AS, UA). Due to the low incidence 
of RA, few cases occur simultaneously or just after pregnancy. Consequently, the previous 
studies were mainly of a matched case-control design (214;222;223). Every study design 
carries the risk of introducing its own type of bias, and a strength of our study is that we have 
confirmed the increased incidence of arthritis post partum in a different setting. In previous 
studies (214;222;223) it was demonstrated that the increased incidence of RA after delivery 
was accompanied by a lower incidence during pregnancy. This suggests that the increased 
incidence of RA after delivery may be due to delayed occurrence of RA until after delivery 
(283). Previous studies have estimated time of disease onset (first symptom), and 
demonstrated a peak incidence during the first year after delivery. We studied time of 
diagnosis, which is probably more precise compared to time of symptom onset due to the 
insidious start of disease. Usually, there will be a delay between disease onset and diagnosis. 
This methodological difference may explain why we found an excess of incident cases even 
in the second year after delivery. Our study was not able to determine whether the observed 
increased incidence after delivery is a true increased incidence or a consequence of delayed 
onset until after delivery.  
 When analysing all incident cases, we found that both RA and OCA were frequently 
diagnosed during the first two years after delivery, but a higher proportion of incident cases 
were observed in the RA group. However, the disease risk did not reach statistically 
significance between the groups. We found a statistically significantly higher incidence rate at 
0-24 months versus 25-48 months post partum in the RA group, but not in the OCA group. 
 When analysing incident cases after birth order one separately, the disease risk did not 
reach statistically significance between RA and OCA. We found a statistically significantly 
more frequent onset of disease during 0-24 months versus 25-48 months post partum in RA. 
For OCA the point estimates of IRR were numerically higher after the first delivery than after 
the second and additional deliveries, but did not reach statistical significance. A similar trend 
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has been reported in two other studies of RA patients (13;223). The previous studies also 
indicated a higher risk of developing arthritis after first birth. 
 Hazes et al found a lower risk of RA in women who had ever been pregnant (13). 
Also, the earlier the first pregnancy occurred, the lower was the risk of developing RA (13). 
Adjustments for birth order and maternal age at delivery in the Cox regression analyses did 
not significantly influence the relative risks for developing disease 0-24 months post partum 
in our study. 
 Overall, our results indicate that a higher incidence of arthritis post partum may not be 
unique for RA. Although a trend was observed after birth order one, it remains to demonstrate 
that there is a peak incidence in OCA post partum. 
 
9.2 Pregnancy and delivery in women with chronic inflammatory arthritides with a 
specific focus on first birth (Paper 2) 
 
Previous studies of pregnancy outcomes in women with CIA versus a reference population 
have used different study designs and different methods for data collection, which make 
comparisons of the results difficult. Three studies were population based with retrospective 
designs (234;239;240). Another study was population based with a cross sectional design 
(233). Three studies have used case-control design (16;235;244), and three other studies were 
of a prospective design (152;232;246). Data collection has often been based on interviews of 
CIA women about pregnancy complications. This method may introduce recall bias. 
However, repeated observed similar findings in studies of different designs may strengthen 
the observations. In most studies the CIA disease status (i.e. level of disease activity, use of 
treatment) have been poorly defined, and the patient cohorts may have been heterogeneous, 
from the mildest to the most diseased women, including patients with and without use of 
DMARDs. Further, some studies have not defined deliveries before or after diagnosis of CIA.  
It has been suggested that RA and other autoimmune diseases have a preclinical 
autoimmune activity and a long prodromal phase, which may be of importance for 
pregnancies (229-231;284-288). Thus, from this perspective it is of particular interest to 
examine pregnancy outcomes before clinical onset and diagnosis of CIA. An advantage of our 
study was the possibility to analyse separately deliveries before and after diagnosis. Separate 
analyses of pregnancy outcomes before diagnosis has, as far as we know, only been done in 
two previous studies (236;246). Both our current data and previous reports indicate that the 
disease effect on pregnancy outcomes does not occur before the disease has been diagnosed.  
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Anti-CCP was included among recorded variables in NOR-DMARD in 2006. The 
majority of the patients in the studies comprising this thesis were included before 2006, and 
we did not have information about anti-CCP status in our analyses. We can not exclude that 
preclinical autoimmune activity is different in subgroups of patients with antibodies 
predicting RA (285-287) with possible influence on pregnancy outcomes. This question 
remains to be examined for pregnancy outcomes before disease onset.  
An advantage of our study was the possibility to do separate analyses on outcomes of 
first births before and after the diagnosis of a rheumatic disease. This approach has not been 
applied in CIA pregnancies previously. No differences in pregnancy outcomes were observed 
between cases and references in first births before diagnosis. The majority of the observed 
differences in outcomes between patients and references were related to first birth in women 
diagnosed with CIA. However, increased rates of CS, both total and elective, were related to 
all births after diagnosis of CIA compared with references. 
 
Assisted reproduction 
Nulliparous CIA women had significantly more assisted reproduction compared with 
references in the unadjusted analysis. Maternal age at delivery was a confounding factor for 
assisted reproduction. Thus, adjusted, the difference was no longer statistically significant. 
The frequency of assisted reproduction has not been reported in CIA women before. The 
patient group in our study was older than references at time of first delivery, which may 
reflect that these women had experienced problems with attaining pregnancy. Reduced 
fertility has been reported for CIA women (258;259). A limitation of our study is that we did 
not know how many women who had tried assisted reproduction and not attained pregnancy.   
   
Vaginal bleeding 
Patients had a twofold higher risk of vaginal bleeding compared with references in 
pregnancies related to first birth. Use of NSAIDs among the patients during pregnancy might 
be one cause of this observed increased risk. No previous reports exist on a possible relation 
between use of NSAIDs and bleeding in pregnancy. Such use is easy to underestimate 
because patients may limit their report to prescribed drugs and not include over-the counter 
purchases.  
We did not observe any excess risk of bleeding during delivery. Patients are advised 
not to use NSAIDs after 32 gestational weeks, and this may explain why we did not observe 
higher risk of bleeding during delivery. 
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Unfortunately, our study had insufficient information about the use of medication 
during pregnancy since most women stopped DMARD medication before they achieved 
pregnancy and were withdrawn from the NOR-DMARD-registry. 
 
Labour induction and Caesarean section (CS) 
Increased use of labour induction was observed in nulliparous patients compared with 
references. Only one previous study has reported a higher rate of labour induction in CIA 
women, but not specifically in relation to first birth (240). Increased CS rates have been 
reported from several studies and from different geographic areas (233-235;240). Our study 
confirmed significantly increased rates of CS, both elective and total, related to all deliveries 
after a diagnosis of CIA. We found a doubled rate of elective CS, both in first and subsequent 
births after diagnosis. Placental dysfunction, cephalopelvic disproportion and combined 
causes constituted each one third of the indications. Arthritic women may have stiffness and 
pain indicating inflammation, and obstetricians may choose to do CS because they anticipate 
problems during delivery. Women with AS had the highest occurrence of elective CS (25 %) 
among the different diagnostic groups, which may be due to inflammation and / or ankylosis 
in the sacroiliac joints and the lumbal spine, and vaginal birth may be especially difficult to 
women with AS. 
 Interestingly, we found no increase in acute CS rate in patients with CIA. The two 
dominating reasons for acute CS in Norway are labour dystocia and fetal distress (289). We 
did not observe differences in labour dystocia between patients and references. In Norway, 
vaginal birth after one caesarean delivery (VBAC) has been the rule for many years. We do 
not think this rule is different for women diagnosed with CIA, but we were not able to adjust 
for this possibility since we lacked information about sibships among the references. 
 
The newborn 
The risks of preterm delivery and SGA were higher for first born infants of mothers diagnosed 
with CIA compared with references, but not for infants of patients with subsequent births. 
Previous studies have reported increased risks of both preterm delivery and SGA without 
relating this to birth order (234;235;238).  
The proportion of infants with birth weight less than 2500 gram was similar between 
patients and references, both for first born children and subsequent birth orders. However, we 
observed small, but statistically significantly differences, crude and adjusted, in mean birth 
weights and head circumferences in first born infants of women diagnosed with CIA, but not 
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in infants of subsequent births after diagnosis. Birth weight and head circumference may be 
related to placental function (290-292), but also to other factors, i.e. genetically. One previous 
study has reported that both high level of disease activity and use of low doses of prednisone 
during pregnancy may reduce birth weight (152). Unfortunately we did not have data of 
disease activity scores during pregnancy since most women were withdrawn from the NOR-
DMARD registry during pregnancy.  
We found no differences with regard to major congenital malformations between cases 
and references in contrast to previous reports (237;239). We did not have power to examine 
specific birth defects, post perinatal mortality or outcomes in each diagnostic group 
separately. Three of four children reported with perinatal deaths were first born children of 
mothers diagnosed with CIA. The perinatal mortality rate was 3 times higher in the children 
of CIA women compared with references. The result was statistically significant, but with 
wide confidence intervals and should be interpreted with caution. In a retrospective study of 
RA women, excess of perinatal deaths were reported in infants of mothers who subsequently 
developed RA after delivery (237), but has not been reported among infants of mothers 
diagnosed before delivery. 
The observed higher frequency of events in first births may be accounted for by 
selective fertility after a CIA diagnosis, since women with the highest disease activity would 
most likely have only one child. However, all women in this study had active disease treated 
with synthetic or biological DMARDs, and were presumable among CIA women with highest 
disease activity. Another hypothesis is that immunological processes of the inflammatory 
disease influence first birth more than later pregnancies. Further studies on outcomes of first 
births in women diagnosed with CIA are needed to confirm our findings.  
 
 
9.3 Fertility in women with chronic inflammatory arthritides (Paper 3) 
 
In our study of fertility in women diagnosed with CIA, fertility was defined as the actual 
production of offspring. Previous studies have reported inconsistent observations about 
fertility in CIA women compared with references. There may be several reasons for this. Most 
studies have been restricted to women with RA and the patient cohorts have often been poorly 
defined and possibly heterogeneous. Other studies have small sample sizes (260). Further, 
selection bias in both cases (only cases who plan pregnancy) and controls (friends, 
neighbours, relatives, newspaper advertising) may have influenced the results.  
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An advantage of the present study was the birth year matched references from the 
National Population Registry. We did not have information about educational level of the 
references, but educational level was similar in nulliparous (childless) and parous (para 1+) 
patients. The Norwegian population comprises about 95 % Caucasians and is 
socioeconomically a rather homogenous population compared with many other countries. The 
country has public health care and social security systems covering all citizens and which are 
particularly beneficial to families with small children. However, we can not exclude possible 
socioeconomic differences between patients and references biasing our results.  
Another advantage of our study was that we examined a defined patient cohort 
constituting the most severely diseased women treated with synthetic and / or biological 
DMARD. However, our results should be interpreted with caution and may not be generalized 
to all CIA women. 
 
Nulliparity 
Four previous studies of RA patients, one also including AS patients, have estimated fertility 
by including nulliparous patients (258;260;261;293). Nulliparity was in our study defined as 
lack of match in MBRN. We can not exclude that some of these women might have delivered 
in another country, but this possibility is probably minimal. Inclusion of nulliparous patients 
and references is therefore a strength of our study. A higher proportion of women diagnosed 
with CIA were nulliparous compared with age matched references. When we examined each 
diagnostic group separately, the proportion of nulliparity reached statistical significance for 
patients diagnosed with OCA and JIA, but not for RA women. Only one of the previous 
publications of nulliparity in RA women showed a statistically significantly higher rate 
compared with references, but three studies showed an increased trend among the patients 
(258;260;293). The study including patients with RA and AS showed no difference in 
nulliparity between patients and references (261). The very high proportion of nulliparous 
women among both JIA patients and their references in our study was most probably due to 
the younger age of this group (mean age of about 30 years at time of data linkage). Nulliparity 
has been discussed as a risk factor for RA (13;25;223;258;293;294), but to our knowledge 
nulliparity has not been discussed as a possible risk factor for OCA.  
In the present study we did not know how many of the nulliparous women who had 
tried to become pregnant, which is a limitation of the study. We also lacked information about 
use of contraceptives among patients and references. All patients were using DMARDs. Since 
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many DMARDs are incompatible with pregnancy, the patients are advised to use  
contraceptives regularly, which might have introduced a bias in our results. 
Previous studies have discussed several causes of nulliparity in women diagnosed with 
CIA. Non-remitting disease and functional impairment have been reported to reduce the wish 
for children in women with CIA (245;257). Health status may influence sexual activity and 
increased levels of fatigue, pain and mental distress have been reported among factors with 
negative impact on sexual activity in patients with RA (295-297). Also, severe disease flares 
have been reported to lower sexual activity more than physical handicap (298;299). Further, 
some patients have expressed concern about risk of arthritic disease in offspring, which may 
contribute to reduced fertility rates (300). Women with arthritis may also be concerned about 
their ability to physically take care of a child (300). Previous population based studies have 
reported an overrepresentation of various gynaecological disorders and surgery of the genital 
tract in women with rheumatic diseases (301;302) which could also contribute to a higher 
proportion of nulliparous women. In the present study we did not have data of associated 
gynaecological disorders. 
 
Fertility rates 
Overall, we observed that the patients mean number of children was associated with age at 
time of CIA diagnosis. This observation is also in accordance with another study (257). 
Women diagnosed after 30 years of age had a mean number of children comparable to the 
reference group, most probably because women diagnosed in the fourth decade have delivered 
the desired number of children before disease onset. We did not observe any differences in 
relative fertility rates in RA and OCA women compared with references before disease onset. 
Our findings contrasts two previous publication where a lower fertility rate was reported prior 
to disease onset in RA (258;293). Especially, a lower fertility rate was concentrated in a 
rheumatoid factor subgroup of patients (258). We did not examine rheumatoid factor positive 
subgroups due to small numbers. Additionally, the proportion of rheumatoid factor positive 
patients was low in the OCA group. In the two previous studies, selection of controls from the 
same geographical area as the patients may have biased the results. 
RA, OCA and JIA women had significantly lower relative fertility rates after 
diagnosis. These observations are in agreement with previous studies (253;257;258;293). A 
possible contributing explanation to the reduced relative fertility rates we observed may be a 
heavy disease burden of the study population. The JIA group might be even more selected as 
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JIA patients in need of DMARDs constitutes about 50 % of the patient population diagnosed 
in childhood, and most of them have polyarticular disease (104).  
We observed a higher proportion of CS in patients compared with references (Article 
2), and this is also reported in previous studies (233-235;240). A Norwegian study has 
reported that women with CS at first delivery will have fewer children than a woman who 
starts with a vaginal birth (303). This may also contribute to the observed reduced number of 
children in the patient group. 
 
Inter pregnancy interval 
We observed an increased inter pregnancy interval for RA and OCA women diagnosed 
between first and second birth, which indicate that women diagnosed after first birth may 
postpone a second pregnancy until the disease is better controlled.  To our knowledge no 
previous studies have reported this interval before. 
No differences in inter pregnancy intervals were observed for women with all births 
after diagnosis. This is in contrast to another study where an increased interval after diagnosis 
was reported (253). These findings may indicate that improved treatment options during the 
last decade give better disease control and opportunities to continue to a second pregnancy. 
Our findings could also indicate that women with all births after diagnosis want to have their 
children within a shorter time period. Additionally, RA patients continuing to a second 
pregnancy were significantly older than the references at time of first delivery, giving a 
shorter reproduction period. This observation is in accordance with a Norwegian population 
based cohort study (253), but in contrast to observations in a Canadian case-control study of 
women with recent onset RA (260). Different study populations and study designs might 
explain the different results. The Canadian study examined women with new onset RA 
(within 3 years) and had a small sample size. 
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10 Conclusions and implications 
 
10.1 Answers to research questions 
 
10.1.1 Paper 1 
 
 The proportions of incident cases with onset 0-24 months after delivery were not 
statistically significantly different between RA and OCA 
 
 
 A statistically significant peak in incident cases 0-24 months versus 25-48 months post 
partum was seen in the RA group, both when considering all deliveries and only the 
first delivery 
 
 A peak incidence was also observed in the OCA group after the first pregnancy 0-24 
months versus 25-48 months post partum, but the result did not reach statistically 
significance. 
 
10.1.2 Paper 2 
 
 All negative diverging pregnancy outcomes in patients versus references were 
observed in relation to first birth after diagnosis: 
 
 
o A statistically significant excess of vaginal bleeding was observed 
 
o A statistically significantly higher risk of labour induction was observed. 
 
o Statistically significantly lower mean birth weight and smaller head 
circumference were observed. 
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o Statistically significantly higher rates of preterm deliveries and SGA children 
were observed. 
 
o A statistically significantly higher rate of perinatal mortality was observed. 
 
 A statistically significantly higher risk of CS (total and elective) was related to all 
births in women diagnosed with CIA. 
 
 Pregnancy outcomes before diagnosis did not differ from the reference population.  
 
 
10.1.3 Paper 3 
 
 A statistically significantly higher proportion of nulliparous women were observed for 
all CIA women compared with birth year matched references. 
 
 The proportion of nulliparous women reached statistical significance within the 
diagnostic groups for OCA and JIA, but not for RA compared with age matched 
references.  
 
 
 The mean number of children was associated with age at time of CIA diagnosis. 
 
 Relative fertility rates were statistically significantly reduced for all diagnostic groups 
after diagnosis,  
 
 Relative fertility rates were not statistically significantly different between cases and 
references before diagnosis for any of the diagnostic groups. 
 
 Inter pregnancy interval was statistically significantly increased in women with first 
birth before and second birth after diagnosis of CIA. 
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 Inter pregnancy interval was not statistically significantly different between patients 
and references when first and second birth were after diagnosis of CIA. 
 
 
 
10.2 Clinical implications 
 
Our study of women with CIA aged 18-45 years and treated with synthetic or biological 
DMARDs has shown that not only RA, but also other chronic arthritides frequently are 
diagnosed the first two years after delivery. Our study indicates that serious rheumatic 
diseases needing treatment with DMARDs, may start post partum. Doctors should pay special 
attention to women with onset of all kinds of arthritic symptoms in this period of life.   
First births were associated with more negative outcomes for women diagnosed with 
CIA and their infants compared with references. For clinician this finding indicates particular 
awareness and regular controls when monitoring CIA women in their first pregnancy. No 
previous studies have examined outcomes of first births in women diagnosed with CIA 
separately, and our study needs confirmation. Our study indicated an increased risk of 
perinatal mortality in first born children of women diagnosed with CIA. However, we did not 
find other serious adverse outcomes for the children of the patients. Overall, our findings 
indicate that women with CIA should not be advised against having children because of 
possible risks of serious adverse outcomes. The recurrent observations of a higher rate of CS 
in CIA women after diagnosis should lead to obstetric attention to indications of CS in these 
women.  
Our observation that most negative outcomes were associated with first births, also 
generate a new hypothesis that immunological processes of the inflammatory disease may 
influence first birth more than later births. Pregnancy outcomes were not affected for any birth 
order before onset of CIA, but we could not exclude that specific subgroups of patients may 
be affected in pregnancies. Future studies should focus on subgroups of patients i.e. anti-CCP 
positive / negative women versus references to examine if certain subgroups have higher risks 
for adverse pregnancy outcomes before manifest clinical disease.  
Starting a family is of central importance in many people’s life, also in CIA patients 
(300), however, our study indicates that women with CIA have reduced family size. We also 
observed a higher proportion of childless women in each of the diagnostic groups compared 
 69
with birth year matched references. We were not able to answer how many of the childless 
women had tried to become pregnant, and future studies should also take childbearing choices 
into account. We examined patients with high disease activity scores and reduced functional 
status. Thus, our results of pregnancy outcomes and reproduction can not be generalised to all 
women with CIA. However, we think that more women with CIA would profit from 
professional, individual advice before pregnancies. 
  Several aspects of reproduction concern women with CIA, and evidence based 
knowledge is necessary to counsel patients in these questions. After the introduction of 
biological DMARDs, clinicians are frequently asked about the impact of these medications on 
pregnancy. Improvements in the medical treatment of arthritides may not immediately lead to 
increasing fertility rates, but future trends will be of interest. Another aspect of future 
attention may be that women in Western countries more frequently postpone their first 
pregnancy until the fourth decade of life. Consequently, the proportion of patients with CIA 
becoming pregnant after disease onset will increase, which will have impact on the need for 
counselling and monitoring of these patients.  
 
 
 
 
 
 
11. Erratum 
Paper 1: Patients, Materials and Methods: Setting (page 332): data of women from the NOR-
DMARD registry linked with MBRN should read 631  
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DAS28  2,6 = remission 
 
 
 
Notification forms for the Medical Birth Registry of Norway in use from 1967-1998 and 
from Dec 1, 1998 
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Abstract 
Objective: To examine possible associations between chronic inflammatory 
arthritides (CIA) and pregnancy outcomes with separate analyses of first and 
subsequent births before and after diagnosis. 
Methods: Linkage of data from a CIA patient registry and the Medical Birth 
Registry of Norway enabled a comparison of pregnancy outcomes in CIA- and 
non CIA-women. Outcomes of first birth and subsequent births before and after 
diagnosis were analysed separately. Associations between CIA and the women’s 
health during pregnancy and delivery as well as perinatal outcomes were assessed 
in logistic regression analyses with adjustments for maternal age at delivery and 
gestational age.  
Results: We analysed 128 first births and 151 subsequent births after diagnosis 
and corresponding 286 /262 births before diagnosis versus references.  First born 
children of women diagnosed with CIA were more often preterm (OR 1.85 (1.09, 
3.13)) and small for gestational age (OR 1.60 (1.00, 2.56)). They also had lower 
mean birth weight (p= 0.01) and higher perinatal mortality (OR 3.26 (1.04, 
10.24)). Birth by caesarean section (CS) (all classifications) was more frequent in 
patients than references, and elective CS was twofold more frequent in patients, 
both in first birth (OR 2.60 (1.43, 4.75)) and subsequent births (OR 2.18 (1.33, 
3.58)). No excess risks were observed prior to CIA diagnosis. 
Conclusion:  Excess risks were related to first birth in women diagnosed with 
CIA, including a higher rate of perinatal mortality. A higher CS rate was related to 
all patient deliveries. Pregnancy outcomes before diagnosis did not differ from the 
reference population. 
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It is increasingly recognised that autoimmunity can affect every aspect of  
pregnancy such as fertilisation, maternal complications and adverse fetal 
outcomes (1). Also, pregnancy may influence autoimmune diseases. An 
ameliorating effect of pregnancy on chronic inflammatory arthritides (CIA)  has 
been reported (2-8). Several studies have addressed possible effects of CIA on 
pregnancy and delivery (9-22). Excess rates of caesarean section (CS) have been 
reported in patients with CIA (9;10;12;15-17;21). Furthermore, excess rates of 
preeclampsia (12;19;21;22), preterm delivery (17;19;20), infants small for 
gestational age (SGA) and low birth weight < 2500 g (9;12;19;20) have been 
reported. One study found a slightly increased rate of birth defects in infants of 
mothers with CIA (20). Two studies found no differences in perinatal, neonatal or 
infant death (20;23), but one study found increased perinatal mortality in infants 
of mothers diagnosed with rheumatoid arthritis (RA) after delivery (18).  
However, further studies of CIA and pregnancy outcomes are necessary because 
effects may change over time (20;21) due to improvements of diagnostic tools and 
medical treatments as well as changes in routines of registration of obstetric 
practice.  
Another relevant issue is that effects of subclinical disease processes on 
pregnancy outcomes can not be  excluded since a status of preclinical RA may 
exist (24-26). Two previous studies have reported specifically on pregnancy 
outcomes in women before a diagnosis of CIA without any observed differences 
between patients and references (23;27). 
Pregnancy and delivery complications are more frequent in first pregnancy 
and delivery (28-30). The risk of CS in nulliparous women with spontaneous start 
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of labour, cephalic fetus and no previous scar has been reported to be 2.5 times 
higher than for comparable parous women (31).  The causes for this increased risk 
are not fully understood, although it has been known for more than 40 years 
(32;33). Separate analyses of outcomes of first birth and subsequent births in 
women with CIA have not been previously published. 
The aim of the present study was to examine possible different effects of 
CIA on pregnancy outcomes with separate analyses of outcomes in first and 
subsequent births in women treated with disease modifying antirheumatic drugs 
(DMARDs). Further, we wanted to examine if a possible negative association 
with pregnancy outcomes was detectable before diagnosis of CIA.  
 
Material and methods: 
Setting 
The Medical Birth Registry of Norway (MBRN) (34;35) comprising more than 
2.2 million births 1967 – 2008, used the same notification form 1967 - 1998. This 
form comprised data on all live births as well as stillbirths after 16 weeks of 
gestation. A more detailed form was introduced December 1, 1998 which 
comprises data on all births after 12 weeks of gestation (35). Data on 
complications, maternal disease and mode of delivery were entered into the 
notification form as free text until 1998 and in checkboxes or as free text from 
1999 onward. The forms are filled in by birth attendants within one week of 
delivery. The record includes data on the mother’s health at birth, before and 
during pregnancy and characteristics of the newborn within the first week after 
delivery. Data from the MBRN are routinely linked to the Cause of Death 
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Registry by the national identification number to obtain information on infant 
mortality. 
                Since 2001 patients with CIA have been enrolled into the Norwegian 
Disease Modifying Antirheumatic Drug (NOR-DMARD) registry. Patients are 
included when they start with a synthetic or biological DMARD and withdrawn 
when they discontinue DMARD medication. Several patients in the registry were 
diagnosed before 2001 and may or may not have used DMARDs before inclusion. 
The NOR-DMARD registry has previously been described in detail (36).  
                 Data of female patients aged 18 – 45 years at the time of inclusion in 
the NOR-DMARD registry in the period 2001-2006 were included in the present 
study. All patients had signed a written informed consent form before enrolment 
in the NOR-DMARD registry. In addition, eligible women received written 
information about the planned linkage of NOR-DMARD and MBRN data. 
Fourteen women opted out, and data of 631 women from the NOR-DMARD 
registry were linked with the MBRN. The linkage included deliveries from 1970 
until October 2007. The study was carried out in compliance with the Helsinki 
Declaration, and was approved by the Norwegian Data Inspectorate, the Regional 
Ethics Committee of Central Norway and the Norwegian Directorate of Health. 
 
Exposure 
The study population included women with RA, psoriatic arthritis (PsA), 
ankylosing spondylitis (AS) and unspecified arthritis (UA) diagnosed before 45 
years of age, and adult patients with juvenile idiopathic arthritis (JIA) (diagnosed 
before 16 years of age). UA comprised patients without fulfilment of criteria of a 
specified arthritis. In the analyses all diagnoses were combined into a group called 
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chronic inflammatory arthritides (CIA). All patients were diagnosed by 
rheumatologists before or at enrolment in the NOR-DMARD registry, and the 
time of diagnosis was recorded during enrolment. Only data for single births were 
analysed. Data were stratified for births before and after time of diagnosis of CIA. 
               The reference deliveries were frequency sampled from non-CIA 
deliveries in MBRN. The proportion of deliveries were equal for each decade 
among CIA patients and references. This procedure created two reference groups 
comprising a total of 800000 reference deliveries after diagnosis and 1000000 
before (Table 1). 
 
Outcome 
Data on parity and gestational age from week 16 were retrieved from MBRN. 
First birth was defined as the first delivery of nulliparous women. We also 
collected data from MBRN on maternal characteristics, assisted reproduction (all 
methods combined) and pregnancy complications (i.e. all reported vaginal 
bleeding in pregnancy (all trimesters combined), preeclampsia (preeclampsia and 
eclampsia)(37;38), induction of labour (amniotomy, oxytocin and prostaglandin), 
preterm delivery (<37 weeks of gestation), instrument-assisted deliveries (vacuum 
extraction or the use of forceps), excessive bleeding during delivery (> 500 ml), 
labour dystocia (prolonged delivery >24 hours, mechanical disproportion or 
uterine dysfunction /atony), caesarean section (CS) (total, elective and acute).  
                MBRN also provided data on the newborn (gender, head circumference, 
birth weight) and transfer to the neonatal intensive care unit (NICU). Birth defects 
included serious (major) malformations in any organ system and were defined 
according to a definition by MBRN based on International Classification of 
 7
Arthritis and pregnancy 
Diseases (ICD)-8 (1967-1998) and ICD-10 (1999 and onwards). Perinatal 
mortality included stillbirths ( 22 weeks of gestation) and early neonatal deaths 
(0-6 days in live born children). 
                
Analyses 
Data were analysed in strata comprising first births and subsequent births. Group 
comparisons were performed with Mann-Whitney U test for continuous variables 
and chi-square tests for categorical variables. Associations between CIA and 
adverse perinatal outcomes were assessed in logistic regression analyses with 
adjustments for maternal age. In addition, the analyses of transfer to NICU and 
birth weight < 2500 g as dependent variable were adjusted for gestational age. 
Mean birth weights and mean head circumferences were analysed in multiple 
linear regression analyses with covariates for gestational age, gender, maternal 
age and parity. Data were analysed using the Statistical Package of Social 
Sciences, version 16.0 (SPSS Inc., Chicago, Illinois, USA) and Statistics / Data 
Analysis (STATA), version 10.1 (StataCorp, Lakeway drive College Station, 
Texas, USA). 
 
Results 
Of 631 eligible women from the NOR-DMARD registry, 393 (62 %) were also 
registered in the MBRN.  Table 1 shows patient characteristics stratified for 
deliveries after and before diagnosis as well as reference characteristics. CIA 
women with first delivery after diagnosis were significantly older than the 
references at time of delivery (p<0.001). Opposite, cases with first delivery before 
diagnosis were significantly younger than the references (p<0.001). Deliveries 
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(first birth / subsequent births (%)) after diagnosis of CIA across main diagnostic 
groups in NOR-DMARD were as follows: RA (45.3 / 54.3), PsA (14.1 / 13.2),  
AS (8.6 / 8.6), UA (7.8 / 10.6) and JIA (24.2 / 13.2). 
 
First birth after diagnosis (Table 2) 
Assisted reproduction was significantly more frequent in CIA women compared 
to references in the crude analysis. The statistically significant difference 
disappeared after adjustment. Vaginal bleeding in pregnancy was more frequently 
reported in CIA women, both for crude and adjusted comparisons.  
We found increased risk of CS, (both total and elective) in CIA women 
compared to the reference population. There was no difference in acute CS.  
A statistically significantly higher rate of labour induction was also observed 
among the patients.  
 We observed more preterm deliveries and small for gestational age infants 
among CIA women. Infants of CIA women also had lower mean birth weight and 
smaller head circumference than infants of references. (Table 4). Unadjusted, 
more children of CIA women had birth weight < 2500 gram, but adjusted the 
difference was not statistically significant.      
 We found statistically significantly increased perinatal mortality among 
infants of CIA women compared to references. 
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Subsequent births after diagnosis (Table 3) 
We observed excess CS rates, (both total and elective) in patients compared to 
references. We did not observe any other differences between patients and 
references.  
 
Births before diagnosis (Online supplementary Tables S1, S2 and S3) 
No differences were observed in outcomes between cases and references in first 
birth before receiving CIA diagnosis. Except for an increased risk of preeclampsia 
after adjustment for maternal age at delivery, we did not find other worse 
outcomes for cases compared to references in subsequent births.  
 
 
Discussion  
In this first study with separate analyses of outcomes of first birth and subsequent 
births in women with CIA, the observed differences between patients and 
references were related to first birth after diagnosis of CIA and not to subsequent 
births, except for CS. 
We observed a higher frequency of assisted reproduction for nulliparous 
CIA women compared to references unadjusted, but not adjusted (Table 2). We 
have not found any previous studies reporting the frequency of assisted 
reproduction in CIA women. Age was a confounding factor for assisted 
reproduction (Table 2). This patient group was older at the time of first delivery 
(Table 1), which may reflect that these women had experienced more problems 
with attaining pregnancy. Reduced fertility has previously been reported for 
women with CIA (39;40), but we do not know how many women who had tried 
assisted reproduction and not attained pregnancy.    
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          Patients had a twofold higher risk of vaginal bleeding compared to 
references in pregnancies related to first birth (Table 2). Use of non steroidal anti-
inflammatory drugs (NSAIDs) among the patients may be the cause of this 
observed increased risk. No previous reports exist on a possible relation between 
use of NSAIDs and bleeding in pregnancy. Unfortunately, we did not have 
registrations of use of NSAIDs during the pregnancy. Such use is easy to 
underestimate because patients may limit their report to prescribed drugs and not 
include over-the-counter purchases. We did not observe any excess risk of 
bleeding during delivery. Patients are advised not to use NSAIDs after 32 
gestational weeks, and this may explain why we did not observe higher risk of 
bleeding during delivery. 
A higher rate of labour induction was observed for women with first birth, 
but not for subsequent births (Table 2, Table 3). Only one previous study has 
reported a higher rate of labour induction, but not specifically in relation to first 
birth (21). We found an increased CS rate (total and elective) both in first and 
subsequent births (Table 2, Table 3). Higher CS rate in patients with CIA has been 
reported in several previous studies and from different countries (9;12;15-
17;19;21), but the causes of high CS rates have been less explored. We found a 
doubled rate of elective CS; both in first and subsequent births. We did not find 
any specific obstetric diagnoses or indications responsible for the increased rate of 
CS. Placental dysfunction, cephalo-pelvic disproportion and combined causes 
constituted each one third of the indications for CS. Women diagnosed with AS 
had the highest occurrence of CS (25 %) among the different diagnostic groups. 
The high occurrence of elective CS could be attributed to stiffness and pain in 
CIA patients and especially in the pelvic region of AS women. Furthermore, 
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obstetricians may choose to do an elective CS because they anticipate problems 
during delivery. Interestingly, we found no increase in acute CS rate. The two 
dominating reasons for acute CS in Norway are labour dystocia and fetal distress 
(41). We did not observe differences in risks of labour dystocia between patients 
and references (Table 2, Table 3). In Norway, vaginal birth after caesarean 
delivery (VBAC) has been the rule after one CS for many years. We do not think 
this rule is different for CIA women, but we were not able to adjust for this 
possibility since we lacked information about sibships among the references. 
Birth weight was analysed in three ways: mean birth weight (Table 4), the 
number of children born small for gestational age (SGA) and the number of 
children with birth weight less than 2500 gram. All observed differences were 
related to first birth after diagnosis. The risks of both SGA and preterm delivery 
were increased for first birth (Table 2). This finding is in accordance with 
previous reports of CIA birth outcomes (12;17;19;20), but has not been examined 
separately for first born children before .  
Unadjusted, more infants of the patients had birth weight less than 2500 
gram compared to children of the references, but after adjustment the difference 
disappeared. Taking into consideration gestational age, gender and maternal age at 
delivery in the multiple linear regression analysis, we observed small, but 
statistically significantly differences in both mean birth weight and head 
circumference in the first- born children after diagnosis compared to references 
(Table 4). Both birth weight and head circumference are related to the placental 
function (42-45). One previous study has reported that a high level of disease 
activity and also the use of low doses of prednisone during pregnancy may 
influence birth weight negatively (11). Most female CIA patients who are 
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planning pregnancies, stop DMARDs incompatible with pregnancy several 
months before they attain pregnancy. In the NOR-DMARD registry patients are 
withdrawn when they stop a DMARD regimen, which unfortunately leads to lack 
of scores and current medication during pregnancy and often immediately before. 
We found improved outcomes for infants compared with other reports, as 
we found no differences in birth defects or the need of transfer to neonatal 
intensive care unit (18;20). However, we observed a higher perinatal mortality 
related to first birth (Table 2). The rate was 3 times higher in the children of CIA 
women compared to references, but the result should be interpreted with caution 
because of the wide confidence intervals. Increased risk of perinatal deaths in 
infants of mothers who subsequently developed RA after delivery has been 
reported (18), but not in infants of mothers diagnosed before delivery. The current 
study did not have power to examine differences in specific birth defects or to do 
separate analyses within each diagnostic group.  
A strength of this study was the possibility to analyse separately deliveries 
before time of diagnosis (online supplementary Tables S1, S2 and S3). This has 
only been done in two previous studies without observing any harmful effects on 
pregnancy outcomes (23;27). Some studies have suggested preclinical 
autoimmunity and a long prodromal phase in RA and other autoimmune diseases 
(24-26;46-49). From this perspective it is of particular interest also to examine 
pregnancy outcomes before clinical evident CIA. Except for a higher risk of 
preeclampsia in cases compared to references in subsequent pregnancies, we did 
not find any associations with poor pregnancy outcomes before diagnosis, 
indicating that the disease effect on pregnancy outcomes does not occur before the 
disease has been diagnosed. However, we cannot exclude that this is different in 
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subgroups of patients, for example in subgroups with antibodies predicting RA 
(25;49).  
Our focus in the analyses was deliveries, not women. To account for the 
possibility of carrying on adverse events from one delivery to another involving 
dependence, adjustment by using mixed models could have been done. We were 
not able to do this adjustment because we lacked information about sibships 
among the references. However, most differences were observed in first births in 
which this bias does not exist.   
Adjustment for smoking habits during pregnancy was not done because of 
insufficient information. This is a limitation of the study and of potential 
importance when studying birth weight. Another limitation was lack of 
information on educational level of the references since socioeconomic status may 
influence the level of pregnancy care. However, all pregnant women in Norway 
are offered pregnancy care free of charge with a participation rate close to 100 %, 
and we do not think lack of this information has biased the results.  
The observed higher frequency of events in first births may be accounted 
for by selective fertility after a diagnosis of CIA, since women with the highest 
disease activity would most likely have only one child. However, all women in 
this study had active disease treated with synthetic or biological DMARDs, and 
were presumably among CIA women with highest disease activity. Another 
hypothesis is that immunological processes of the inflammatory disease may 
influence the first birth more than later births. Further studies on outcomes of first 
births after diagnosis are needed to confirm our findings. 
In summary, the observed differences in pregnancy outcomes between 
CIA patients and references were related to first birth after diagnosis, including an 
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increased rate of perinatal mortality in the infants of the patients. An increased CS 
rate was related to all pregnancies after diagnosis. Pregnancy outcomes before 
diagnosis did not differ from the references. Overall, our findings indicate that 
special attention should be given to the first birth in women diagnosed with CIA. 
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Table 1 Patient and reference characteristics, first birth and subsequent births, after 
and before diagnosis of CIA (mean (SD) for continuous variables, n (%) for counts).  
 Deliveries 
after 
diagnosis 
References p-value Deliveries 
before 
diagnosis 
References p-value 
Total number of 
deliveries  
 
279 
 
800000 
  
548 
 
1000000 
 
First birth 128  
(45.9) 
335249 
(41.9) 
 286  
(52.2) 
423532 
(42.3) 
 
Age at delivery 
(years) 
28.8  
(4.7) 
26.9  
(4.8) 
<0.001 24.9  
(4.5) 
25.9 (4.7) <0.001 
Gestational age 
(days) 
276.6 
(18.7) 
278.7 
(19.4) 
0.17 280.7 
(14.3) 
280.0 
(18.3) 
0.82 
Subsequent births 151  
(54.1) 
464751 
(58.1) 
 262 
(47.8) 
576468 
(57.7) 
 
Age at delivery 
(years) 
31.5 
(4.1) 
30.8 
(4.6) 
0.04 28.6 
(4.4) 
30.1 
(4.7) 
<0.001 
Gestational age 
(days)  
276.9 
(18.0) 
278.9  
(16.9) 
0.16 279.7 
(13.4) 
280.0  
(17.1) 
0.14 
CIA= chronic inflammatory arthritides, SD= standard deviation 
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Table 2 Crude and adjusted odds ratios of pregnancy outcomes in first births after CIA 
diagnosis versus reference deliveries  
 Cases 
n=128 
n (%) 
References 
n=335249 
n (%) 
 
 
  
 
 
OR 
 
 
CI 
 
 
p-value 
Assisted reproduction 5 (3.9) 5224  (1.6) C 2.63 1.05, 6.28 0.04 
   A* 1.77 0.69, 4.53 0.23 
Pregnancy complications       
Vaginal bleeding in pregnancy 8 (6.3) 10216 (3.0) C 2.12 1.04, 4.34 0.04 
   A* 2.01 1.00, 4.13 0.05 
Preeclampsia  4 (3.1) 17095 (5.1) C 0.60 0.22, 1.62 0.31 
   A* 0.59 0.22, 1.61 0.31 
Delivery        
CS, total 29 (22.7) 48955 (14.6) C 1.71 1.13, 2.59 0.01 
   A* 1.51 1.00, 2.29 0.05 
CS, elective 12 (9.4) 10917 (3.3) C 3.07 1.70, 5.57 <0.001 
   A* 2.60 1.43, 4.75 0.002 
CS, acute 16 (12.5) 33262 (9.9) C 1.30 0.77, 2.19 0.33 
   A* 1.16 0.69, 1.97 0.57 
Labour induction, total 32 (25.0) 55483 (16.5) C 1.68 1.13, 2.51 0.01 
   A* 1.61 1.08, 2.41 0.02 
Labour dystocia 43 (33.6) 103922 (31.0) C 1.12 0.78, 1.62 0.53 
   A* 1.03 0.71, 1.48 0.89 
Instrument-assisted deliveries 22 (17.2) 48197 (14.4) C 1.27 0.80, 2.01 0.31 
   A* 1.18 0.74, 1.87 0.48 
Bleeding>500 ml during delivery 11 (8.6) 40690 (12.1) C 0.68 0.37, 1.26 0.22 
   A* 0.62 0.33, 1.16 0.13 
Infant       
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Birth weight< 2500 gram 12 (9.4) 16714 (5.0) C 1.96 1.08, 3.55 0.03 
   A** 1.94 0.87, 4.34 0.10 
Preterm delivery 16 (12.5) 23119 (6.9) C 1.91 1.13, 3.24 0.01 
   A* 1.85 1.09, 3.13 0.02 
SGA (<10 percentile) 21 (16.4) 36451 (10.9) C 1.59 0.99, 2.54 0.05 
   A* 1.60 1.00, 2.56 0.05 
Transfer to NICU 10 (7.8) 18747 (5.6) C 1.48 0.75, 2.92 0.26 
   A** 1.19 0.56, 2.51 0.65 
Major congenital malformations 4 (3.1) 10186 (3.0) C 1.03 0.38, 2.79 0.95 
   A 0.96 0.35, 2.60 0.93 
Perinatal mortality  3 (2.3) 2427 (0.7) C 3.29 1.05, 10.35 0.04 
   A* 3.26 1.04, 10.24 0.04 
C=crude, A=adjusted, OR= Odds ratio, CI= confidence interval, CS= caesarean section, 
SGA= small for gestational age, NICU= neonatal intensive care unit 
 
*   adjusted for maternal age at delivery 
** adjusted for maternal age at delivery and gestational age 
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Table 3 Crude and adjusted odds ratios of pregnancy outcomes of CIA deliveries after 
diagnosis versus reference deliveries, subsequent births  
 Cases 
n=151 
n (%) 
References 
n=464751 
n (%) 
  
 
OR 
 
 
95% CI 
 
 
p-value 
Assisted reproduction 1 (0.7) 2504 (0.5) C 1.23 0.17, 8.79 0.84 
   A* 1.16 0.16, 8.31 0.88 
Pregnancy complications       
Vaginal bleeding in pregnancy 7 (4.6) 14461 (3.1) C 1.51 0.71, 3.23 0.28 
   A* 1.50 0.70, 3.19 0.30 
Preeclampsia  3 (2.0) 10924 (2.4) C 0.84 0.27, 2.64 0.77 
   A* 0.82 0.26, 2.58 0.74 
Delivery        
CS, total 30 (19.9) 54792 (11.8) C 1.85 1.24, 2.77 0.002 
   A* 1.79 1.19, 2.68 0.004 
CS, elective 18 (11.9) 26176 (5.6) C 2.27 1.39, 3.71 0.001 
   A* 2.18 1.33, 3.58 0.002 
CS, acute 12 (7.9) 25015 (5.4) C 1.52 0.84, 2.74 0.17 
   A* 1.47 0.81, 2.66 0.19 
Labour induction , total 19 (12.6) 61017 (13.1) C 0.95 0.59, 1.54 0.84 
   A* 0.94 0.58, 1.51 0.79 
Labour dystocia 24 (15.9) 62515 (13.5) C 1.21 0.78, 1.88 0.38 
   A* 1.19 0.77, 1.84 0.43 
Instrument-assisted deliveries 3 (2.0) 14062 (3.0) C 0.67 0.21, 2.09 0.49 
   A* 0.65 0.21, 2.04 0.46 
Bleeding >500 ml during delivery 15 (9,9) 40904 (8.8) C 1.14 0.67, 1.95 0.62 
   A* 1.12 0.66, 1.91 0.67 
Infant       
Birth weight < 2500 gram 3 (2.0) 15998 (3.4) C 0.57 0.18, 1.78 0.33 
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   A** 0.23 0.03, 1.76 0.16 
Preterm delivery   8 (5.3) 23762 (5.1) C 1.05 0.51, 2.15 0.89 
   A* 1.03 0.51, 2.11 0.93 
SGA (<10 percentile) 11 (7.3) 29986 (6.5) C 1.15 0.62, 2.13 0.65 
   A* 1.17 0.63, 2.16 0.62 
Transfer to NICU 0  18272 (3.9)     
       
Major  congenital malformations 3 (2.0) 11047 (2.4) C 0.83 0.26, 2.61 0.75 
   A* 0.82 0.26, 2.57 0.73 
Perinatal mortality   1 (0.7) 3173 (0.7) C 0.97 0.14, 6.93 0.97 
   A* 0.95 0.13, 6.79 0.96 
C= crude, A= adjusted, OR= odds ratio, CI= confidence interval, CS= caesarean section, 
SGA= small for gestational age, NICU= neonatal intensive care unit 
 
*   Adjusted for maternal age at delivery  
** Adjusted for maternal age at delivery, parity and gestational age 
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Table 4 Multiple linear regression analysis of birth weight and head 
circumference in offspring of CIA patients, first birth and subsequent births after 
diagnosis (mean (SD)) 
 
First birth     
  Patients 
(n=128) 
References 
(n=335249) 
p-
value 
 Birth weight* (gram) 3287.7 
(647.3) 
3454.7 
(614.4) 
0.01 
 Head circumference* (cm) 
 
34.7 
(2.0) 
35.0 
(1.9) 
0.05 
Subsequent births     
  Patients 
(n=151) 
References 
(n=464751) 
p-
value 
 Birth weight** (gram) 3548.7 
(597.2) 
3610.1 
(624.4) 
0.52 
 Head circumference** (cm) 35.1 
(2.2) 
35.3 
(1.8) 
0.15 
SD=standard deviation, cm=centimeter 
* Analyses with covariates for gestational age, gender of child and maternal age at 
delivery 
** Analyses with covariates for gestational age, gender of child, maternal age at 
delivery and parity 
 

Supplementary Table S1 Crude and adjusted odds ratios of pregnancy related outcomes 
in first births before CIA diagnosis versus reference deliveries  
 Cases 
n=286 
n (%) 
References 
n=423532 
n (%) 
 
 
 
 
 
OR 
 
 
CI 
 
 
p-value 
Assisted reproduction 3 (1.0) 3395 (0.8) C 1.31 0.42, 4.09 0.64 
   A* 1.95 0.61, 6.16 0.26 
Pregnancy complications       
Vaginal bleeding in pregnancy 2 (0.7) 10886 (2.6) C 0.27 0.07, 1.07 0.06 
   A* 0.27 0.07, 1.10 0.07 
Preeclampsia 14 (4.9) 19738 (4.7) C 1.05 0.61, 1.80 0.85 
   A* 1.06 0.62, 1.82 0.82 
Delivery        
CS, total 43 (15.0) 54958 (13.0) C 1.19 0.86, 1.64 0.30 
   A* 1.29 0.93, 1.79 0.13 
CS, elective 3 (1.0) 9757 (2.3) C 0.45 0.14, 1.40 0.17 
   A* 0.51 0.16, 1.60 0.25 
CS, acute 27 (9.4) 30251 (7.1) C 1.35 0.91, 2.01 0.13 
   A* 1.59 0.99, 2.19 0.06 
Labour induction, total 55 (19.2) 76982 (18.2) C 1.07 0.80, 1.44 0.64 
   A* 1.10 0.82, 1.48 0.53 
Labour dystocia 53 (18.5) 83602 (19.7) C 0.92 0.69, 1.25 0.61 
   A* 0.98 0.73, 1.33 0.92 
Instrument assisted deliveries 31 (10.8) 58181 (13.7) C 0.77 0.53, 1.12 0.18 
   A* 0.81 0.56, 1.18 0.28 
Bleeding >500 ml during delivery 23 (8.0) 33055 (7.8) C 1.03 0.67, 1.58 0.88 
   A* 1.08 0.70, 1.65 0.73 
Infant       
Birth weight< 2500 gram 13 (4.5) 21523 (5.1) C 0.89 0.51, 1.55 0.68 
   A** 1.02 0.51, 2.04 0.95 
Preterm delivery 20 (7.0) 26687 (6.3) C 1.10 0.70, 1.74 0.67 
   A* 1.11 0.71, 1.76 0.64 
SGA (<10 percentile) 36 (12.6) 51399 (12.1) C 1.03 0.72, 1.46 0.89 
   A* 1.02 0.72, 1.44 0.92 
Transfer to NICU 5 (1.7) 7128 (1.7) C 1.76 0.66, 4.67 0.25 
   A** 1.68 0.58, 4.85 0.34 
Major congenital malformations 6 (2.1) 10995 (2.6) C 0.80 0.36, 1.80 0.60 
   A 0.83 0.37, 1.86 0.65 
Perinatal mortality 2 (0.7) 3845 (0.9) C 0.77 0.19, 3.09 0.71 
   A* 0.77 0.19, 3.08 0.71 
CIA= chronic inflammatory arthritides, C= crude, A= adjusted, OR= Odds ratio,  
CI= confidence interval, CS= caesarean section, SGA= small for gestational age,  
NICU= neonatal intensive care unit 
 
* adjusted for maternal age at delivery 
**adjusted for maternal age at delivery and gestational age 
 
 
 
 
 Supplementary Table S2 Crude and adjusted odds ratios of pregnancy related outcomes 
of CIA deliveries before diagnosis versus reference deliveries, subsequent births 
 Cases 
n=262 
n (%) 
References 
n=576468 
n (%) 
 
 
 
 
OR 
 
 
CI 
 
 
p-value 
Assisted reproduction 0 1432 (0.2) C    
   A*    
Pregnancy complications       
Vaginal bleeding in pregnancy 1 (0.4) 15919 (2.8) C 0.13 0.02, 0.96 0.05 
   A* 0.14 0.02, 0.98 0.05 
Preeclampsia 10 (3.8) 12315 (2.1) C 1.81 0.96, 3.42 0.06 
   A* 1.93 1.03, 3.64 0.04 
Delivery        
CS, total 25 (9.5) 59242 (10.3) C 0.92 0.61, 1.39 0.69 
   A* 1.01 0.67, 1.53 0.95 
CS, elective 10 (3.8) 22117 (3.8) C 0.99 0.53, 1.87 0.99 
   A* 1.15 0.61, 2.16 0.67 
CS, acute 12 (4.6) 22924 (4.0) C 1.16 0.65, 2.07 0.62 
   A* 1.27 0.71, 2.26 0.42 
Labor induction, total 44 (16.8) 84775 (14.7) C 1.17 0.85, 1.62 0.34 
   A* 1.21 0.87, 1.67 0.25 
Labor dystocia 20 (7.6) 47514 (8.2) C 0.92 0.58, 1.45 0.72 
   A* 0.96 0.61, 1.52 0.87 
Instrument assisted deliveries 4 (1.5) 15800 (2.7) C 0.56 0.21, 1.49 0.24 
   A* 0.59 0.22, 1.60 0.30 
Bleeding >500 ml during delivery 21 (8.0) 33320 (5.8) C 1.42 0.91, 2.21 0.12 
   A* 1.46 0.94, 2.29 0.09 
Infant       
Birth weight < 2500 gram 9 (3.4) 20148 (3.5) C 0.99 0.51, 1.93 0.99 
   A** 1.27 0.57, 2.84 0.56 
Preterm delivery 12 (4.6) 28218 (4.9) C 0.94 0.53, 1.69 0.85 
   A* 0.98 0.55, 1.75 0.94 
SGA (<10 percentile) 14 (5.3) 43085 (7.5) C 0.71 0.41, 1.22 0.21 
   A* 0.69 0.40, 1.19 0.18 
Transfer to NICU 4 (1.5) 7068 (1.2) C 1.04 0.37, 2.90 0.94 
   A** 0.73 0.21, 2.51 0.62 
Major congenital malformations 5 (1.9) 12232 (2.1) C 0.90 0.37, 2.17 0.81 
   A* 0.93 0.38, 2.25 0.87 
Perinatal mortality  3 (1.1) 4883 (0.8) C 1.35 0.43, 4.23 0.60 
   A* 1.39 0.44, 4.35 0.57 
CIA= chronic inflammatory arthritides, C= crude, A= adjusted, OR= odds ratio,  
CI= confidence interval, CS= caesarean section, SG= small for gestational age,  
NICU= neonatal intensive care unit 
 
* Adjusted for maternal age at delivery and parity   
**Adjusted for maternal age at delivery, parity and gestational age 
Supplementary Table S3 Multiple linear regression analysis of birth weight and head 
circumference in offspring of cases versus references, first birth and subsequent births 
before CIA diagnosis (mean (SD)) 
First birth     
  Patients 
(n=286) 
References 
(n=423532) 
p-
value 
 Birth weight* (gram) 3489.3  
(540.8) 
3440.5 
(610.2) 
0.23 
 Head circumference* (cm) 34.9  
(2.5) 
35.0  
(1.8) 
0.50 
Subsequent births     
  Patients 
(n=262) 
References 
(n=576468) 
p-
value 
 Birth weight** (gram) 3644.5 
(591.9) 
3593.3 
(618.0) 
0.18 
 Head circumference (cm)**  35.4  
(1.6) 
35.3  
(1.7) 
0.08 
CIA= chronic inflammatory arthritides, SD=standard deviation, cm=centimeter 
* Analyses with covariates for gestational age, gender of child and maternal age at 
delivery 
** Analyses with covariates for gestational age, gender of child, maternal age at delivery 
and parity 
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Abstract 
Objective: To compare fertility rates in women with rheumatoid arthritis (RA), 
other chronic arthritides (OCA) and juvenile idiopathic arthritis (JIA) with 
reference women from the general population. 
Methods: Each woman from a Norwegian patient registry was matched by year 
of birth with 100 reference women randomly selected from the National 
Population Registry. Data linkage of patients and references with the Medical 
Birth Registry of Norway (MBRN) identified all offspring in patients and 
references until October 2007, and indirectly also nulliparous (childless) women. 
Groups were compared with Mann-Whitney U-test for continuous variables and 
chi-square tests for categorical variables. Poisson regression analysis was applied 
to calculate relative fertility rates in the diagnostic groups versus references. 
Results Among 631 patients 849 children were registered in MBRN. Of  these, 
289 children (34.0 %) were born after time of diagnosis versus 44.3 % in 
references. Altogether 206 of 631 patients (32.6 %) were nulliparous versus  
26.4 % in references (p<0.001). Among RA patients 28.4 % (96 of 338) were 
nulliparous versus 24.5 % in references (p=0.09), 30.7 % (67 of  218) in OCA 
patients versus 24.5 % in references (p=0.03) and  57.3 % (43 of 75) in JIA 
patients versus 40.9 % in references (p=0.004). Adjusted relative fertility rates in 
RA, OCA and JIA after diagnosis were 0.88, 0.84 and 0.84, respectively, 
compared with references.  
Conclusion: A higher proportion of women with chronic inflammatory arthritides 
were nulliparous compared with references, and relative fertility rates were 
reduced in all patient groups. 
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Introduction 
Chronic inflammatory arthritides (CIA) may influence the production of  
offspring (fertility) due to different mechanisms: physical, psychological, 
hormonal or immunological as well as medical treatments [1].  
Fertility has particularly been studied in rheumatoid arthritis (RA). Some 
studies have indicated reduced sexual desire and lower frequencies of intercourse 
in women with RA [2-4].  In a report with structured interviews of about 400 
married women with RA, nearly one in five patients answered that RA influenced 
childbearing decisions, and especially in women diagnosed at a young age [5]. 
The overall percentage of women having children was not different from the 
general population, but women with RA were more likely to opt for a single child. 
Data obtained in cross-sectional surveys have suggested low ability to 
conceive a child and longer time to achieve pregnancy in RA  patients both before 
and after disease onset [6, 7]. However, a case- control study with age matched 
controls did not find any association between RA and low fertility [8]. 
Few publications exist on fertility in other chronic arthritides. In 
ankylosing spondylitis (AS) three studies have reported normal fertility [9-11], but 
longer time to achieve pregnancy has been reported in one study [11]. 
Women diagnosed with juvenile idiopathic arthritis (JIA) may experience 
long-term physical and psychosocial impairment [12]. In one study fertility was 
not impaired in JIA women [13], but longer time to achieve pregnancy has been 
reported [13, 14]. 
Previous studies have examined fertility in heterogeneous patient groups, 
from the worst to the mildest affected women. We wanted to study fertility among 
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the most severely affected patients, i.e. women treated with synthetic or biological 
disease modifying antirheumatic drugs (DMARDs). The aim of the study was to 
compare fertility rates in women with RA, other chronic arthritides (OCA) and 
JIA with birth year matched references from the general population.  
 
Material and Methods: 
Setting 
Since 2001 data of patients with CIA have been recorded in the Norwegian 
Disease Modifying Antirheumatic Drug (NOR-DMARD) registry. Patients are 
enrolled when they start with a synthetic or biological DMARD, but many of the 
patients have been diagnosed and have used DMARDs several years before 
enrolment. The NOR-DMARD registry has previously been described in detail 
[15]. 
Since 1967 medical data on all births in Norway have been recorded in the 
Medical Birth Registry of Norway (MBRN)[16, 17].  From 1967 to 1998 the 
registry collected data on all births in Norway after 16 weeks of gestation. Since 
1999 all births after 12 weeks of gestation have been registered. The records 
include demographic data on the parents and their reproductive history. 
The study was performed in accordance with the Helsinki declaration and 
approved by the Norwegian Data Inspectorate, the Regional Ethics Committee of 
Central Norway and the Norwegian Directorate of Health. Permission to use 
references from the Norwegian Population Registry was approved by The 
Norwegian Tax Authorities and the Regional Ethics Committee of Central 
Norway.  
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Patients 
Patients from the NOR-DMARD registry enrolled 2001- 2006 were included in 
the present cohort study. All patients had signed a written informed consent form 
before enrolment. In addition, eligible women received written information about 
the planned linkage of NOR-DMARD data and MBRN. Fourteen women opted 
out, and data of 631 women from the NOR-DMARD registry were linked with the 
MBRN including deliveries until October 2007. All patients were diagnosed by a 
rheumatologist before or at enrolment in the NOR-DMARD registry. 
  Due to low numbers, the women with psoriatic arthritis (PsA), AS and 
unspecified arthritis (UA) were analysed as an entity labelled other chronic 
arthritides (OCA). UA comprised patients without fulfilment of criteria of a 
specified arthritis. Thus, the study population included 338 women with RA, 218 
with OCA and 75 adult patients with JIA, all diagnosed before 45 years of age, 
(JIA before 16 years of age).  
         Time of diagnosis was recorded by a rheumatologist when the patient was 
enrolled in the NOR-DMARD registry. Data on maternal age at delivery, birth 
order, date of last menstrual period, date of birth and gestational age were 
retrieved from MBRN. Nulliparous (childless) women were identified by lack of 
match in MBRN. Inter pregnancy interval was defined as the time period from the 
date of the first birth to the first day of the last menstrual period preceding the 
second birth. 
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Reference population 
Each patient was matched by year of birth with 100 reference women randomly 
selected from the Norwegian Population Registry, totally 63100 references. All 
references were linked to the MBRN to identify all offspring.  
 
Analysis 
For group comparisons, Mann-Whitney U test was used for continuous variables 
and chi-square test for categorical variables. Date of diagnosis for each patient 
was linked to the corresponding references to analyse pre- and post diagnosis 
parity.  
Poisson regression analysis was applied to estimate relative fertility rates 
in women with RA, OCA and JIA before and after diagnosis versus birth-year 
matched references with adjustment for parity at time of diagnosis when relevant.  
Regression analysis by Locally Weighted Scatterplot Smoothing 
(LOWESS fit) was used to calculate and visualise mean number of children by 
age of diagnosis (Figure 1).  
Cox regression analysis with adjustment for maternal age at first delivery 
was used to compare the interval between first and second birth  in patients and 
references. 
 Two-sided p values of <0.05 were interpreted as significant. Data were 
analysed using the Statistical Package of Social Sciences, version 17.0 (SPSS Inc., 
Chicago, Illinois, USA) and Statistics / Data Analysis (STATA), version 11.0 
(StataCorp, Lakeway Drive College Station, Texas, USA). 
 
Results 
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Among the 631 patients 849 children were registered in MBRN. Of  these, 289 
children (34.0 %) were born after time of diagnosis versus 44.3 % in references.  
In the diagnostic groups 147 children were registered in the RA group, 89 in the 
OCA group and 53 in the JIA group after diagnosis (Table 1). 
Altogether 206 of 631 (32.6 %) patients were nulliparous versus 26.4 % in 
references (p<0.001) at time of censoring (October 2007). Among RA patients 
28.4% (96 of 338) were nulliparous versus 24.5 % in references (p=0.09), 30.7 % 
(67 of  218) in OCA patients versus 24.5 % in references (p=0.03) and  57.3 % 
(43 of 75) in JIA patients versus 40.9 % in references (p=0.004) (Table 1).  
Mean number of children was lower in patients than references (Figure 1). 
Especially, this difference was marked in women diagnosed before 30 years of 
age. In women diagnosed after age 30 years, mean number of children approached 
that of the age matched references.  
Adjusted relative fertility rates in RA, OCA and JIA after diagnosis were 
0.88, 0.84 and 0.84, respectively (Table 2). Relative fertility rates in patients 
before diagnosis were not reduced (Table 2). 
In the analyses of inter pregnancy interval 38 patients had their first 
delivery before they received a diagnosis of CIA and the second delivery after 
diagnosis (Table 3). Further, 70 patients had all deliveries after time of diagnosis. 
We observed significantly increased inter pregnancy intervals in RA and OCA 
women diagnosed between first and second birth. No differences in the intervals 
were observed in any of the diagnostic groups with both first and second birth 
after diagnosis (Table 3). 
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Discussion 
In this study of CIA patients treated with synthetic or biological DMARDs, a 
higher proportion of patients were nulliparous compared to age matched 
references (p<0.001). When examining each diagnostic group separately, the 
proportion of nulliparity reached statistical significance for patients diagnosed 
with OCA and JIA, but not for RA women. The high proportion of nulliparous 
women among JIA patients and references was probably due to the younger age 
of this group with a mean age of about 30 years at time of data linkage (Table 1). 
Only three previous studies of RA patients have reported the proportion of 
nulliparous women [6, 8, 18], and all with an excess of nulliparity among patients.  
Nulliparity has been discussed as a risk factor for RA [6, 18-22], but to our 
knowledge nulliparity has not been discussed as a risk factor for OCA.  
More likely, our observation of a higher proportion of nulliparity among 
CIA patients may be caused by non remitting disease and functional impairment, 
which have previously been reported to reduce the wish for children in women 
with CIA [5, 14]. Also, severe disease flares have been reported to lower sexual 
activity [23, 24]. Further, some patients have expressed concern about risk of 
arthritic disease in offspring, which may contribute to reduced fertility rates [25], 
and two previous studies have reported that women with RA and JIA sometimes 
are advised against having offspring [12, 25].  
Previous population based studies have reported an overrepresentation of 
various gynaecological disorders and surgery of the genital tract in women with 
rheumatic diseases [26, 27], which could also contribute to a higher proportion of 
nulliparity. In the present study we did not have data of associated gynaecological 
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disorders, and we did not know how many of the nulliparous women had tried to 
become pregnant. We also lacked information about use of contraceptives among 
patients and references. In the present study all patients were using DMARDs. 
Since many DMARDs are incompatible with pregnancy, the patients are advised 
to use contraceptives regularly.   
  RA, OCA and JIA women had significantly lower relative fertility rates 
after diagnosis (Table 2). The results are in accordance with two previous studies 
[5, 28]. One possible contributing explanation to the reduced fertility rates may be 
the heavy disease burden of the study population. JIA women in the study were 
probably even more highly selected. Adult JIA patients treated with synthetic and 
/ or biological DMARDs constitutes about 50 % of all patients diagnosed in 
childhood, and many of them have or will develop polyarticular disease [29]. 
Several studies of women with CIA have reported an increased frequency 
in Caesarean deliveries (CS) compared to references [10, 14, 30-34].  Unpublished 
data from the present patient population has also shown an increased risk of CS 
among the patients compared to references (data under review). A Norwegian 
study has reported that a woman with CS as her first delivery will have fewer 
children than a woman who starts with a vaginal birth [35]. This may also 
contribute to the observed reduced number of children in the patient group. 
Overall, we observed that the mean number of children was associated 
with age at time of CIA diagnosis (Figure 1), which is in accordance with 
previous reports of RA [5, 28]. Women diagnosed after 30 years of age had a 
mean number of children comparable to the reference group. 
We did not observe any differences in the relative fertility rates in RA and 
OCA women versus references before disease onset (Table 2). Our finding 
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contrasts a previous publication  where lower fertility rate was reported prior to 
disease onset in RA, and especially lower fertility rate was concentrated in a 
rheumatoid factor positive subgroup of patients [6]. We did not examine 
rheumatoid factor positive subgroups due to small numbers. Especially, the 
proportion of rheumatoid factor positive patients was low in the OCA group.     
We observed an increased inter pregnancy interval for RA and OCA 
women diagnosed between first and second birth. The increased interval indicates 
that women diagnosed after first birth may postpone a second pregnancy until the 
disease is better controlled. To our knowledge no other studies have reported this 
interval specifically before. No differences in inter pregnancy intervals were 
observed for women with first and second birth after diagnosis (Table 3). This 
contrasts another study reporting an increased interval after diagnosis [28]. The 
different findings may be explained by improved treatment options during the last 
decade giving better disease control and opportunities to continue to a second 
pregnancy. Further, our findings indicate that women giving birth after diagnosis 
have their children within a shorter time frame. RA women with their first birth 
after diagnosis were older than references at the time of first delivery, and had less 
time left of their reproductive age (Table 3).  
A strength of the present study was the use of references randomly 
selected from the general population. Some previous studies have used controls 
which might bias the results (i.e. friends, newspaper advertisements or controls 
living in same geographical area as the patients). We did not have information 
about educational level of the references which is a limitation of the study, but we 
did not observe significantly differences in educational level between nulliparous 
and parous patients for any of the diagnostic groups (results not shown).  
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Starting a family is of central importance in many people’s life, also in 
CIA patients [25]. More knowledge around different aspects of fertility, both 
physical and psychological, is necessary to counsel CIA patients in this regard. 
After the introduction of biological DMARDs, clinicians are frequently asked 
about fertility aspects of CIA. Improvements in the medical treatment of 
arthritides may not immediately lead to increased fertility rates, but future studies 
of fertility rates will be of interest, including factors taking personal childbearing 
choices into account.   
We summarise that a higher proportion of CIA women treated with 
DMARDs were childless compared with references. Reduced relative fertility 
rates were observed for all diagnostic groups, which add to the burden of CIA in 
general. 
 
 
Key messages:  
A higher proportion of women with chronic inflammatory arthritides were 
childless compared with birth year matched references. 
 
Relative fertility rates were reduced in women with RA, OCA and JIA compared 
with references. 
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Table 1 CIA patients with references in diagnostic subgroups with numbers of 
nulliparous women and numbers of deliveries total and per woman 
CIA= chronic inflammatory arthritides, RA= rheumatoid arthritis, OCA= other 
 Deliveries total and number per 
woman 
Mean age at time of 
data linkage (years)  
 Patients Nullipara 
n (%) 
Total Before 
diagnosis 
After 
diagnosis 
Para 1+ Nullipara 
Total patients 631 206 
(32.6) 
849 
1.35 
560 
0.89 
289 
0.46 
NS NS 
Total references 
 
63100 16658 
(26.4) 
101728 
1.61 
56670 
0.90 
45058 
0.71 
NS NS 
RA patients 338 96 
(28.4) 
501 
1.48 
354 
1.05 
147 
0.43 
41.1 36.7 
RA references 
  
33800 8281 
(24.5) 
56870 
1.68 
35656 
1.05 
21214 
0.63 
41.0 36.3 
OCA patients 
 
218 67 
(30.7) 
295 
1.35 
206 
0.94 
89 
0.41 
40.7 35.2 
OCA references 
 
21800 5341 
(24.5) 
35928 
1.65 
21013 
0.96 
14915 
0.68 
39.9 36.1 
JIA patients 75 43 
(57.3) 
53 
0.71 
0 53 
0.71 
38.2 29.9 
JIA references 
 
7500 3067 
(40.9) 
8930 
1.19 
0 8930 
1.19 
36.1 29.5 
chronic arthritides, JIA= juvenile idiopathic arthritis, NS= not stated 
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Table 2 Relative fertility rates (RFR) in patients from the NOR-DMARD registry 
versus references, before and after diagnosis 
Group Diagnosis  RFR  95% CI p-value 
RA Crude 0.88 0.83, 0.93 <0.001 
 Adjusted* 0.88 0.84, 0.93 <0.001 
OCA Crude 0.84 0.78, 0.90 <0.001 
 Adjusted* 0.84 0.78, 0.90 <0.001 
After 
diagnosis 
JIA  0.84 0.77, 0.92 <0.001 
RA  0.99 0.96, 1.03 0.89 Before 
diagnosis OCA  0.99 0.95, 1.04 0.78 
*Adjusted for parity 
RA=rheumatoid arthritis OCA=other chronic arthritides  JIA=juvenile idiopathic 
arthritis 
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Table 3 Inter pregnancy intervala in relation to time of diagnosis, crude * and 
adjusted for maternal age at first delivery ** 
Group Diagnosis Age at 
first 
delivery 
patients 
(mean) 
Age at 
first 
delivery 
references
(mean) 
p-
value 
Median 
interval 
patients
(years) 
Median 
interval 
references 
(years)  
p-value 
 
 
RA 
(n=22) 
25.3 25.3 0.90 3.5 2.3 0.004* 
0.003** 
       
OCA 
(n=16) 
25.3 25.3 0.91 4.6 2.1 0.001* 
0.002** 
First birth 
before 
diagnosis, 
second 
birth after 
diagnosis   
       
 
RA 
(n=36) 
 
28.1 
 
25.2 
 
<0.001
 
2.6 
 
2.2 
 
0.33* 
0.82** 
       
OCA 
(n=17) 
26.9 25.2 0.09 1.9 2.2 0.64* 
0.74** 
       
JIA 
(n=17) 
25.0 25.2 0.94 2.5 2.3 0.56* 
0.39** 
 
First and 
second 
birth after 
diagnosis 
       
 a Analysis on single births 
RA= rheumatoid arthritis, OCA= other chronic arthritides (psoriatic arthritis, 
ankylosing spondylitis and unspecified arthritis combined), JIA= juvenile 
idiopathic arthritis 
 
 
 
 
 
 
 
 
 
 
 
 18
Arthritis and fertility 
 19
Figure 1 Mean number of children in all patients with chronic inflammatory  
arthritides (CIA) by age at diagnosis  
 
Lowess fit =  regression line 
Scatterplot =  mean number of children, size weighted for the number of patients 
diagnosed per year 
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